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ABSTRACT 
Although some patients with acute leukemia have good prognoses, the prognosis of 
adult and pediatric patients who relapse or cannot tolerate standard chemotherapy is poor. 
Thus, novel therapies are necessary to improve outcomes in acute leukemia. Conventional 
chemotherapy is the mainstay of treatment for acute leukemia, and one approach to 
improving outcomes is to enhance the efficacy of these drugs. Inhibition of the cell cycle 
protein WEE1 has been shown to enhance the efficacy of a number of conventional 
chemotherapy agents by abrogating cell cycle arrest, increasing DNA damage accumulation, 
and promoting apoptosis. Increased understanding of the functions of WEE1 and the 
consequences of WEE1 inhibition, particularly in combination with targeted and non-
targeted agents, will be useful in translating small-molecule WEE1 inhibitors to the clinic. 
 This dissertation seeks to further the understanding of the consequences of WEE1 
inhibition in acute leukemia. Chapter I provides an overview of the clinical characteristics 
and molecular changes in acute myeloid leukemia and acute lymphoblastic leukemia and 
general principles of cell cycle regulation and DNA damage repair. I also review the function 
of WEE1 and pre-clinical and clinical studies with a first-in-class small-molecule inhibitor of 
WEE1, AZD1775. Finally, I review mechanisms of resistance to kinase inhibitors with a 
focus on epigenetic-mediated drug resistance. Chapter II describes the materials and methods 
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used to generate the data presented in this dissertation. In Chapter III, I seek to determine the 
relative contribution of CDK1 and CDK2 to the combinatorial activity of AZD1775 and 
cytarabine. In Chapter IV, I identify a novel synergistic combination in acute leukemia: 
AZD1775 and olaparib. In Chapter V, I characterize three acute leukemia cell lines with 
acquired resistance to AZD1775 and demonstrate that the resistance is mediated by an altered 
epigenetic landscape leading to elevated MYC expression. In Chapter VI, I summarize these 
findings and discuss future directions for this work. Collectively, this work enhances the 
understanding of mechanisms of combinatorial activity of WEE1 inhibition and targeted and 
non-targeted agents and describes a potential mechanism of resistance which can be 
informative in clinical translation. 
The form and content of this abstract are approved. I recommend its publication. 


















To my husband, Jesse, and my parents, Keith and Danita. I am forever grateful for your love, 














 I would like to thank Chris Porter for his guidance and mentorship over the past four 
years. It was an honor and a pleasure to work in the Porter lab, and this experience has been 
invaluable in my career development. I would also like to acknowledge the rest of the former 
Porter lab members for their support, advice, and friendship. I would like to thank Lori 
Gardner and Christy Gearheart for their support and encouragement during this journey and 
Courtney Jones for being a wonderful scientific role model and source of scientific and 
career advice. Thank you to Cathy Lee-Miller who allowed me to shadow her in the clinic 
and has been a great clinical role model. Thank you to Susan Fosmire for being a great lab 
mate in both the Porter and Vibhakar labs and for cloning the CDK1/2-AF constructs. Dmitry 
Baturin trained me to work with mice and assisted in all in vivo studies. Annemie van Linden 
developed the AZD1775-resistant cell lines and performed the AZD1775 and Ara-C 
combination studies in sensitive and resistant cells. Jonathan Snedeker helped with olaparib 
and AZD1775 combination studies.  
 I am greatly indebted to Rajeev Vibhakar for allowing me to work in his lab for the 
past year. It has been a great experience, and my interactions with him and the rest of the 
neuro-oncology team, both in the lab and in the clinic, have solidified my desire to pursue a 
career in pediatric neuro-oncology. Many thanks to rest of the Vibhakar lab for welcoming 
me this past year. Thank you to Sujatha Venkataraman for all the scientific advice she has 
given me and for patiently answering my many technical questions.  
 Many thanks to my thesis committee for their insight and advice and for helping me 
develop as a researcher. 
vii 
 
 I would like to thank the MSTP administration for their support and encouragement. I 
would also like to thank my MSTP classmates for their friendship and advice. It is an honor 
to be a part of such a smart, talented, and kind group of people. Many thanks to my classmate 
Sally Peach for her encouragement, advice, and friendship, and for entertaining me with 
stories of her many world travels. 
 I would like to thank my undergraduate research mentors, Christopher Willey and 
Andrei Stanishevsky, who introduced me to research and inspired me to pursue a career as a 
physician scientist.  
 I would like to thank my husband Jesse for his love and encouragement. Thank you 
for helping me maintain a good work-life balance throughout this journey and for making me 
laugh every day, even when my experiments were not working. Lastly, I cannot thank my 
parents enough for their support and prayers. I am thankful for the sacrifices they have made 
that have enabled me to pursue my dream of being a physician scientist and for instilling in 







Soli Deo Gloria 
viii 
 
TABLE OF CONTENTS 
CHAPTER 
I. INTRODUCTION .....................................................................................................1 
 Acute Myeloid Leukemia ..............................................................................1 
 Acute Lymphoblastic Leukemia ....................................................................6 
 General Principles of Cell Cycle Regulation and DNA Damage Repair .......11 
 WEE1 Tyrosine Kinase..................................................................................21 
 Resistance to Kinase Inhibitors ......................................................................37 
II. MATERIALS AND METHODS ...............................................................................42 
 Cell Culture ....................................................................................................42 
 Lentivirus Preparation ....................................................................................42 
 Chemotherapies, Antibodies, and Reagents ...................................................43 
 Comet Assays.................................................................................................43 
 Immunofluorescence ......................................................................................44 
 Flow Cytometry .............................................................................................44 
 Beta-Galactosidase Staining ..........................................................................44 
 Animal Experiments ......................................................................................45 
 RNAseq ..........................................................................................................45 
ix 
 
 Statistical Analysis .........................................................................................46 
III. INCREASED ACTIVITY OF WEE1 TARGETS CDK1 AND CDK2 IS 
NECESSARY FOR THE COMBINATORIAL ACTIVITY OF AZD1775 AND 
CYTARABINE ......................................................................................................................47 
 Introduction ....................................................................................................47 
 Results ............................................................................................................48 
 Summary of Findings .....................................................................................52 
IV. A SMALL-MOLECULE INHIBITOR OF WEE1, AZD1775, SYNERGIZES    
WITH OLAPARIB BY IMPAIRING HOMOLGOUS RECOMBINATION AND 
ENHANCING DNA DAMAGE AND APOPTOSIS IN ACUTE LEUKEMIA ..................56 
 Introduction ....................................................................................................56 
 Results ............................................................................................................58 
 Summary of Findings .....................................................................................78 
V. ACQUIRED RESISTANCE TO AZD1775 IS MEDIATED BY HDAC 
REGULATED EXPRESSION OF C-MYC ..........................................................................80 
 Introduction ....................................................................................................80 
 Results ............................................................................................................81 
 Summary of Findings .....................................................................................100 
VI. CONCLUSIONS AND FUTURE DIRECTIONS .....................................................103 
x 
 
The Requirement of CDK1 and CDK2 for the Combinatorial Activity of 
AZD1775 and Ara-C......................................................................................104 
Potential Roles of CDK1 and CDK2 in Sensitization to Ara-C ....................106 
Pre-clinical Efficacy of AZD1775 Combined with Olaparib ........................109 
Clinical Considerations of AZD1775 Combined with Ara-C or Olaparib ....111 
The Role of HDACs, KDM5, and c-MYC in AZD1775 Resistance .............115 
Understanding the Clinical Relevance of HDAC-Mediated AZD1775 
Resistance ......................................................................................................117 
Potential Roles for WEE1 in Leukemogenesis ..............................................120 












LIST OF TABLES 
TABLE 
1.1 Small-molecule WEE1 inhibitors ..............................................................................29 
1.2 Summary of pre-clinical studies with AZD1775 .......................................................31 
4.1 Combination index values for MV4;11 cells treated with olaparib and AZD1775     
for 72 hours ................................................................................................................64 


















LIST OF FIGURES 
FIGURE 
1.1 The cell cycle is regulated by CDKs, cyclins, and CDK inhibitory proteins ............14 
1.2 A simplified overview of double-strand break repair by HR and NHEJ ...................16 
1.3 The role of WEE1 in G2/M checkpoint activation ....................................................25 
1.4 Epigenetic mediators of drug resistance ....................................................................39 
3.1 Expression of CDK1-AF and CDK2-AF sensitizes T-ALL cells to cytarabine ........50 
3.2 Expression of CDK1-AF and CDK2-AF increases DNA damage and apoptosis         
in cytarabine-treated cells ..........................................................................................53 
3.3 Inhibition of CDK1 alone or CDK1 and CDK2 reduces the combinatorial activity      
of AD1775 and cytarabine .........................................................................................54 
4.1 Single agent treatment with olaparib or AZD1775 reduces cell viability and    
enhances apoptosis in AML and ALL cell lines ........................................................59 
4.2 AML and ALL cell lines display elevated homologous recombination in response     
to olaparib treatment ..................................................................................................61 
4.3 AZD1775 inhibits homologous recombination in olaparib-treated cells ...................62 
4.4 AZD1775 enhances the anti-proliferative effects of olaparib in acute leukemia      
cells ............................................................................................................................63 
4.5 Inhibition of endogenous P53 in OCI-AML3 cells does not enhance the  
combinatorial activity of AZD1775 and olaparib ......................................................64 




4.7 Combined AZD1775 and olaparib treatment enhances DNA damage      
accumulation, apoptosis induction, and senescence ..................................................68 
4.8 Cell cycle analysis of acute leukemia cells treated with AZD1775 and olaparib ......71 
4.9 Combined AZD1775 and olaparib treatment reduces cell viability and enhances 
apoptosis in a murine AML cell line..........................................................................73 
4.10 Combined treatment with AZD1775 and olaparib improves survival in a murine  
AML model ................................................................................................................74 
4.11 Combined AZD1775 and olaparib treatment is tolerated in vivo ..............................75 
4.12 AZD1775 enhances the anti-proliferative effects of olaparib in AML patient    
samples with high baseline apoptosis or limited colony-forming ability ..................76 
4.13 AZD1775 and olaparib reduce proliferation and colony formation and induce 
apoptosis in AML patient samples .............................................................................77 
5.1 Generation and characterization of AZD1775-resistant cell lines .............................83 
5.2 AZD1775-resistant cells are not broadly resistant to DNA damaging agents ...........86 
5.3 AZD1775-resistant cell lines are resistant to AZD1775 combined with Ara-C ........87 
5.4 HDAC inhibition enhances the anti-proliferative effects of AZD1775 in resistant  
cells ............................................................................................................................89 
5.5 HDAC inhibition enhances DNA damage and apoptosis in resistant cells treated   
with AZD1775 ...........................................................................................................91 
5.6 Cell cycle analysis and CHK1 phosphorylation in AZD1775-sensitive and                   
-resistant cells treated with HDAC inhibitors and/or AZD1775 ...............................93 
5.7 HDAC inhibition enhances the anti-proliferative effects of AZD1775 in cells   
without acquired AZD1775 resistance.......................................................................94 
xiv 
 
5.8 Altered H3K4 trimethylation contributes to AZD1775 resistance ............................96 
5.9 AZD1775-resistant Jurkat cells have elevated c-MYC expression which is    
abrogated with panobinostat treatment ......................................................................98 
5.10 c-MYC expression contributes to AZD1775 resistance ............................................99 


















allo-HSCT ALLOGENEIC HEMATOPOEITIC STEM CELL TRANSPLANT 
AML  ACUTE MYELOID LEUKEMIA  
ANOVA ANALYSIS OF VARIANCE 
APC/C  ANAPHASE-PROMOTING COMPLEX/CYCLOSOME 
Ara-C  CYTARABINE 
ATCC  AMERICAN TYPE CULTURE COLLECTION 
ATM  ATAXIA TELANGECTASIA MUTATED  
ATR  ATM AND RAD3-RELATED 
B-ALL B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 
BER  BREAK EXCISION REPAIR 
BET   BROMODOMAIN AND EXTRATERMINAL DOMAIN 
B-ME  2-MERCAPTOETHANOL  
CAK  CDK-ACTIVATING KINASE 
CDK  CYCLIN-DEPENDENT KINASE 
CI  COMBINATION INDEX 
CML  CHRONIC MYELOID LEUKEMIA 
CNS  CENTRAL NERVOUS SYSTEM 
xvi 
 
COG  CHILDREN’S ONCOLOGY GROUP 
COSMIC CATALOGUE OF SOMATIC MUTATIONS IN CANCER 
CR  COMPLETE REMSSION 
DDR  DNA DAMAGE RESPONSE  
DMSO  DIMETHYL SULFOXIDE  
DNA  DEOXYRIBONUCLEIC ACID 
DNA-PKCS DNA-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT 
dNTP  DEOXYRIBONUCLEOTIDE 
DSB  DOUBLE-STRAND BREAK 
EGFR  EPIDERMAL GROWTH FACTOR RECEPTOR 
FBS  FETAL BOVINE SERUM 
FDR  FALSE DISCOVERY RATE 
FGFR1 FIBROBLAST GROWTH FACTOR RECEPTOR-1 
FLAG-Ida FLUDARABINE, CYTARABINE, GRANCULOCYTE COLONY-
STIMULATING FACTOR, IDARUBICIN 
G-CSF  GRANULOCYTE COLONY-STIMULATING FACTOR 
GFP  GREEN FLUORESCENT PROTEIN 
HDAC  HISTONE DEACETYLASE  
HR   HOMOLOGOUS RECOMBINATION  
xvii 
 
IGF-1R INSULIN GROWTH FACTOR-1R 
IL-3  INTERLEUKIN 3 
ires  INTERNAL RIBOSOME ENTRY SITE 
ITD  INTERNAL TANDEM DUPLICATION 
IVIS  IN VIVO IMAGING SYSTEM 
LDL  LOW DENSITY LIPOPROTEIN 
Mdm2  MURINE DOUBLE MINUTE HOMOLOG 2 
MLL  MIXED LINEAGE LEUKEMIA 
MRD  MINIMAL RESIDUAL DISEASE  
MSCV  MURINE STEM CELL VIRUS 
NCI  NATIONAL CANCER INSTITUTE  
NHEJ  NON-HOMOLOGOUS END-JOINING 
NK  NORMAL KARYOTYPE 
NSCLC NON-SMALL CELL LUNG CANCER 
NuRD  NUCLEOSOME REMODELING AND HISTONE DEACETYLATION 
OS  OVERALL SURVIVAL 
PARP  POLY (ADP-RIBOSE) POLYMERASE 
PBS  PHOSPHATE-BUFFERED SALINE 
xviii 
 
PCNA  PROLIFERATING CELL NUCLEAR ANTIGEN 
PCR  POLYMERASE CHAIN REACTION 
PDGFRβ PLATELET-DERIVED GROWTH FACTOR RECEPTOR β 
PLK1  POLO-LIKE KINASE 1 
Rb  RETINOBLASTOMA 
RFS  RELAPSE-FREE SURVIVAL 
RPA  REPLICATION PROTEIN A 
SCF  STEM CELL FACTOR  
SILAC STABLE ISOTOPE LABELING WITH AMINO ACIDS IN CELL 
CULUTRE 
SSB  SINGLE-STRAND BREAK 
TAE  TRIS BASE, ACETIC ACID, AND EDTA 
T-ALL  T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 










Acute Myeloid Leukemia 
Acute Myeloid Leukemia Epidemiology 
Acute myeloid leukemia (AML) is the most common acute leukemia in adults and the 
second most common leukemia, acute or chronic, in children. In the United States, there were 
approximately 21,000 new cases diagnosed in 2015 alone, and over 10,000 patients died 
from this disease (Siegel et al., 2015). Although AML affects both children and adults, 
incidence increases with age. The incidence of this disease is 1.3 per 100,000 in patients less 
than 65 years old and increases to 12.2 cases in 100,000 in patients over 65 (Kouchkovsky I 
and Abdul-Hay, 2016).  
Survival in young patients diagnosed with AML has significantly improved in recent 
decades due to advances such as risk-directed chemotherapy and novel targeted therapies 
(Dohner et al., 2010; Grimwade and Hills, 2009). In patients 15 to 24 years old at diagnosis, 
5-year survival increased from 7% in 1971 to 53% in 2006 (Shah et al., 2013). During this 
same time interval, the percentage of ‘cured’ patients, defined as patients experiencing 
similar life expectancy as individuals without cancer who possess similar demographic 
characteristics, increased from less than 10% to 48%. Patients in this group who did not 
achieve ‘cured’ status experienced a median survival of roughly 5 months in 1975 which 
increased to 15 months by 2006 (Shah et al., 2013). Despite some success in treatment of 
pediatric and young adult patients, improvements in survival have been less dramatic in 
middle-aged and older adults. Indeed, the 5-year survival rate of individuals 40-59 years old 
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at diagnosis is 33%. Survival rates further decline in elderly patients. The 5-year survival rate 
in patients 60-69 years old is 13%, and this drops to 3% for individuals 70-79 years old 
(Appelbaum et al., 2006; Dores et al., 2012; Shah et al., 2013). The reduced survival rate in 
older patients is particularly concerning as 47% of patients diagnosed with AML are greater 
than 60 years old (Shah et al., 2013). This variation in response with age suggests differing 
disease biology could be partly responsible for the difference in response to therapy. In 
addition to differences in biology, older patients are more likely to have co-morbidities at the 
time of diagnosis, tolerate the intense induction treatment poorly, and are less likely to be 
enrolled in clinical trials (Appelbaum et al., 2006; Buchner et al., 2005).   
Pathophysiology 
While AML arises in patients with congenital disorders affecting DNA damage repair 
pathways, acquired hematologic disorders, or because of prior treatment with DNA 
damaging agents, most cases occur de novo in previously healthy individuals (Albitar et al., 
2002; Gililand and Tallman, 2002; Sill et al., 2011). Experimental and epidemiologic 
evidence has led to the development of a two-hit model of leukemogenesis where two classes 
of mutations are required for AML development (Dash and Gililand, 2001). Class I 
mutations confer a proliferative and/or survival benefit to hematologic progenitors (Kihara et 
al., 2014; Takahashi, 2011). Class I mutations include alterations in FLT3, K/N-RAS, TP53, 
and c-KIT (Network, 2013). Class II mutations impair hematopoietic differentiation and 
include NPM1 and CEBPA as well as PML/RARα and AML1/ETO gene fusions (Gililand and 
Tallman, 2002; Kouchkovsky I and Abdul-Hay, 2016). Recently, a third class of genetic 
modifications that results in alterations of epigenetic modifiers has been described. Altered 
class III genes include IDH1, IDH2, EZH2, TET2, and DNMT3A, and changes in these genes 
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have the potential to influence both proliferation and differentiation (Fathi and Abdel-Wahab, 
2012). One implication of the two-hit model is that there might be therapeutic utility in 
combinations that target genes in each of the classes. 
Risk Assessment 
Accurate assessment of prognosis is critical to the management of AML since factors 
such as risk of treatment resistance and treatment-related mortality are used to determine the 
course of treatment for individual patients. Clinical factors such as increased age, disease 
associated with prior use of DNA damaging agents, and prior history of a hematological 
malignancy are associated with poor rates of complete remission (CR) and overall survival 
(OS) (Hulegardh et al., 2015; Kantarjian et al., 2006). However, the strongest predictors of 
outcome are cytogenetic changes. Cytogenetic changes as well as gene mutations are used to 
stratify AML into favorable, intermediate, and adverse risk groups (Grimwade, 2001; 
Kouchkovsky I and Abdul-Hay, 2016; O'Donnell et al., 2012; Wang and Bailey, 2015). The 
chromosomal rearrangements t(8;21)/RUNX1-RUNX1T1, t(15;17)/PML-RARA, and inv(16) 
are associated with a favorable prognosis (Delaunay et al., 2003; Krauth et al., 2013; Puccetti 
and Ruthhardt, 2004). Additional favorable alterations include mutant NPM1 without FLT3-
ITD (internal tandem duplictation) and biallelic mutant CEBPA (Dohner et al., 2010; Li et al., 
2015; Schlenk et al., 2008). Altogether, patients who have chromosomal or molecular 
markers portending a favorable prognosis experience a CR rate of 80-90%. Roughly 50% of 
de novo AML cases fall into the intermediate risk group. This category contains patients with 
a normal karyotype (NK) or a t(9;11)/KMT2A-MLLT3 chromosomal translocation (Estey, 
2014). While t(8;21) is associated with a favorable prognosis, patients who possess this 
translocation along with a c-KIT mutation have outcomes comparable to patients in the 
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intermediate prognosis group (Qin et al., 2014). Chromosome alterations that confer an 
adverse risk designation include monosomy 5 or 7, t(6;9)/DEK-NUP214, and a complex 
karyotype defined as at least 3 unrelated cytogenetic abnormalities (Chi et al., 2008; Orozco 
and Appelbaum, 2012). Genetic alterations associated with adverse prognosis include 
mutations in methyltransferase genes DNMT3A and KMT2A, FLT3-ITD, even in the presence 
of more favorable factors, and TP53 mutations (Cagnetta et al., 2014; Grossmann et al., 
2012; Port et al., 2014; Shivarov et al., 2013). TP53 mutations occur in less than 10% of 
AML cases, but could be the worst single genetic prognostic factor (Grossmann et al., 2012; 
Network, 2013; Patel et al., 2012). Patients who possess unfavorable cytogenetic markers 
experience a 5-year survival rate of 5-14% (Byrd et al., 2002; Grimwade et al., 1998; 
O'Donnell et al., 2012; Slovak et al., 2000). Finally, response to treatment is used to further 
refine patient prognosis. Patients who achieve CR after induction therapy usually have better 
outcomes than those with treatment resistant disease (Chen et al., 2015). Patients in CR who 
have persistent thrombocytopenia have decreased survival compared to patients in CR 
without thrombocytopenia (Walter et al., 2010). Patients in CR with minimal residual disease 
(MRD) as measured by real-time PCR and flow cytometry also have a worse prognosis than 
patients without MRD (Buccisano et al., 2012). 
Treatment 
  Treatment of AML is divided into two phases of therapy: induction and consolidation 
(Stone, 2013). Standard induction therapy consists of 7 days of cytarabine (Ara-C) 
administered by continuous infusion with 3 days of anthracycline (Kouchkovsky I and 
Abdul-Hay, 2016). An alternative to this consists of fludarabine, Ara-C, granulocyte colony-
stimulating factor (G-CSF), and idarubicin (FLAG-Ida) which has higher rates of CR after 
5 
 
one course (Burnett et al., 2013). An effective induction therapy regimen has not been 
identified in elderly patients, as this patient population is less responsive to chemotherapy 
and more likely to experience treatment-related toxicities. However, when tolerated, 
induction therapy does improve survival over palliative chemotherapy (Lowenberg et al., 
1989). The goal of induction therapy is to achieve CR. In adults, response is assessed two 
weeks after treatment initiation via a bone marrow aspirate (Hussein et al., 2008), and a 
single course of induction therapy induces remission in 50-75% of patients (Board, 2002; 
Fernandez et al., 2009). An additional 26% of patients achieve CR with a second round of 
induction therapy, and OS is comparable between patients achieving CR after one or two 
courses of induction therapy (Rowe et al., 2010).  
MRD is often present in patients in CR, so consolidation therapy is required to 
prevent relapse. Cytarabine is the standard consolidation therapy for patients with a favorable 
prognosis while patients in the intermediate or adverse risk groups benefit from allogeneic 
hematopoietic stem cell transplant (allo-HSCT) (Kouchkovsky I and Abdul-Hay, 2016; 
Yanada et al., 2005). Relapse or refractory AML is treated with salvage therapy. Although 
there are several options for salvage therapy, there is little evidence suggesting one option is 
superior. Therefore, treatment is frequently based on physician preference (Mangan and 
Luger, 2011). Ara-C is often the backbone of salvage therapy, and therapy can consist of 
Ara-C alone or combined with other chemotherapies such as anthracyclines or etoposide or 
as part of FLAG therapy (Mangan and Luger, 2011). Recently, addition of targeted agents 
such as the FLT3 inhibitor quizartinib has effectively prolonged OS for some patients with 
relapsed or refractory disease; however, many of these patients eventually develop resistance 
and succumb to their disease (Hills   et al., 2015). 
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Acute Lymphoblastic Leukemia 
Epidemiology 
Approximately 6,000 new cases of acute lymphoblastic leukemia (ALL) are 
diagnosed each year in the United States (Inaba et al., 2013). Although this disease occurs in 
both children and adults, 55% of patients diagnosed with ALL are younger than 20 years old 
(Hunger et al., 2012). Indeed, the incidence of ALL peaks between 2 and 5 years of age, and 
ALL occurs in 1 in 2,000 individuals ages 0 to 15 (Inaba et al., 2013; Pui et al., 2008).  
Although exogenous and endogenous exposures, genetics, and chance likely contribute to 
ALL development, a full understanding of the contribution of these factors to 
leukemogenesis has been limited for several reasons including the scarcity of ALL in the 
general population and the presence of biologically distinct subtypes with differing etiologies 
(Greaves, 1997). Observations of the peak incidence occurring in early childhood, an 
increased incidence rate in industrialized nations, and the occasional clustering of childhood 
ALL cases has led to two similar hypotheses suggesting ALL results from an abnormal 
immune response to a common infection (Greaves, 2006; Kinlen, 2004; Pui et al., 2008). 
However, while some common viruses have been suggested as possible candidates, a 
transforming virus has yet to be identified (Greaves, 2006; Kroll et al., 2006). Less than 5% 
of ALL cases are associated with predisposing syndromes such as Down’s syndrome, ataxia 
telangiectasia, or Nijmegen breakage syndrome; however, new leukemia predisposing 
conditions continue to be described (Porter, 2016). While individuals with Down’s syndrome 
account for a small percentage of ALL cases, these patients have a 40-fold elevated risk in 




The five-year survival rate for childhood ALL is greater than 80%, but adults and 
infants tend to experience worse outcomes (Pui et al., 2008; Stanulla and Schrappe, 2009). 
ALL in children under 1 year of age displays biology distinct from that of older children and 
is commonly associated with abnormalities in the mixed lineage leukemia (MLL) gene. 
Various groups have reported OS of infantile ALL to be 28-45% (Pieters et al., 2007). 
Likewise, the biological properties of ALL differ between children and adults, and adults are 
more likely to possess chromosomal abnormalities associated with a poor prognosis 
(Smirnova et al., 2016). The overall survival rate in ALL patients 18 to 60 years old is 35% 
(Bassan and Hoelzer, 2011).  
Pathophysiology 
Chromosomal abnormalities occur in the majority of ALL cases (Harrison, 2009). 
Abnormalities observed in B-cell ALL (B-ALL) include high hyperdiploidy, hypodiploidy, 
and translocations such as t(12;21), encoding ETV6-RUNX1(TEL-AML1), t(1;19), encoding 
TCF3-PBX1, and t(9;22), encoding BCR-ABL1. Rearrangements affecting the function of the 
MLL (now referred to as KMT2A) and MYC genes are also frequently observed. These 
alterations can result in impaired hematopoiesis, activated oncogenes, or constitutively active 
kinases (Inaba et al., 2013). Translocations in T-cell ALL (T-ALL) frequently lead to 
oncogenes such as TAL1, TLX1, TLX3, LMO1, LMO2 and, LYL1 becoming juxtaposed to 
promoter and enhancer regions of T-cell receptor genes resulting in their aberrant expression 
(Harrison, 2009; Van Vlierberghe and Ferrando, 2012). Although cytogenetic alterations 
contribute to leukemogenesis, experimental models indicate that additional genetic 
alterations are necessary for the development of ALL (Inaba et al., 2013; Pui et al., 2008). 
The number and type of co-occurring mutations vary based on cell lineage and disease 
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subtype. For example, MLL-rearranged ALL frequently manifests within the first year of life 
and, on average, possesses less than one additional mutation per case. In contrast, ALL with 
gene fusions that typically present later in childhood or adulthood such as ETV6-RUNX1 and 
BCR-ABL1, the most common cytogenetic abnormalities in children and adults, respectively, 
usually display between 6 and 8 additional mutations per case (Inaba et al., 2013). Genes that 
function as regulators of B-cell development are often altered in B-ALL, with PAX5 being 
the most frequently occurring somatic mutation. Other regulators of B-cell development that 
are commonly mutated in B-ALL include E2A, EBF1, LEF1, IKZF1, and IKZF3 (Mullighan 
et al., 2007). Defects in differentiation are also common in T-ALL. Indeed, over 50% of all 
T-ALL cases have activating mutations in NOTCH1 (Grabher et al., 2006; Weng et al., 
2004). Mutations in TP53 and RB1 are rare in T-ALL; however, deletion or epigenetic 
silencing of CDKN2A which encodes downstream effectors P16INK4a and P14ARF via 
alternative reading frames occurs in most childhood T-ALL cases (Krug et al., 2002; Omura-
Minamisawa et al., 2000; Pui et al., 2004a). 
Risk Assessment 
Similar to AML, assessment of the risk of relapse is used to guide therapy of ALL in 
order to achieve remission while sparing low risk patients from the side effects of toxic 
chemotherapy (Pui et al., 2008). The National Cancer Institute (NCI) uses age and presenting 
white blood cell (WBC) count to classify patients as standard or high risk of relapse. Patients 
aged 1 to 9 at diagnosis and presenting with a WBC counts less than 50,000/µL are 
considered to have a standard risk of relapse. Patients that do not fit these criteria are 
classified as having a high risk of relapse (Smith et al., 1996). The Children’s Oncology 
Group (COG) further refines B-ALL classification after induction therapy using biological 
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factors and response to induction therapy to classify patients as low, standard, high, or very 
high risk of relapse (Schultz et al., 2007). Patients with low or standard risk must meet the 
NCI criteria for standard risk. Low risk patients have MRD less than 0.01% as measured by a 
peripheral blood smear 8 days after initiation of induction therapy while standard risk 
patients have MRD between 0.01% and 1%. Genetic factors associated with low relapse risk 
include triple trisomy and a TEL-AML1 gene fusion. Patients with a low relapse risk have a 
5-year event free survival greater than 85%. Factors associated with high risk of relapse 
include those previously designated by the NCI as well as MRD greater than 1% 8 days after 
induction therapy initiation or presence of testicular disease. Genetic factors suggesting a 
very high risk of relapse are possession of a BCR-ABL1 fusion, hypodiploidy with less than 
44 chromosomes, and MLL translocations. Failure to achieve remission after induction 
therapy also suggests a very high risk of relapse. Patients in this group have a 5-year event 
free survival of less than 45% (Schultz et al., 2007). In contrast to B-ALL, there is no 
consensus on prognostic classifications in T-ALL; however, ongoing studies using end-
induction MRD to adjust treatment regimens are promising (Cooper and Brown, 2015) 
Treatment 
Treatment of ALL is divided into four stages: induction, consolidation/intensification, 
CNS-directed, and maintenance therapy. Remission induction therapy lasts 4-6 weeks and 
consists of a glucocorticoid, vincristine, and asparaginase with or without an anthracycline. 
The three drug regimen is sufficient to produce remission in most patients with standard risk 
disease while high risk patients generally require four or more drugs to achieve remission 
(Stanulla and Schrappe, 2009). Induction therapy successfully yields remission in 98% of 
children and 85% of adults (Pui and Evans, 2006). Patients treated with induction therapy 
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alone usually relapse within months of treatment cessation. Thus, consolidation therapy is 
required to eliminate residual leukemic blasts. Consolidation therapy consists of high-dose 
methotrexate with folinic acid rescue, 6-mercaptopurine, and/or asparaginase (Stanulla and 
Schrappe, 2009). Reinduction treatment, repeated induction therapy given once the patient 
has entered remission, is also effective in preventing relapse (Pui et al., 2004b). Allo-HSCT 
can be effective as consolidation therapy in patients with a very high relapse risk such as 
children with a BCR-ABL translocation; however, indications of patients most likely to 
benefit and the potential for different HSCT procedures are still being determined (Pui and 
Evans, 2006; Stanulla and Schrappe, 2009). CNS-directed therapy is a crucial component of 
ALL treatment. Prior to the introduction of CNS-directed therapy, over half of children with 
ALL relapsed, and the use of CNS-directed therapy has reduced this to less than 5% (Pui and 
Howard, 2008; Stanulla and Schrappe, 2009). Cranial irradiation has a number of side effects 
including secondary malignancies and neurocognitive defects and is reserved for patients 
with a high risk of relapse in the CNS. High risk indicators include T-cell phenotype, high 
initial WBC count, and the presence of WBCs in the cerebrospinal fluid (Gajjar et al., 2000; 
Pui and Evans, 2006). Patients who are not at high risk of relapse in the CNS are treated with 
intrathecal chemotherapy or systemic chemotherapies with high CNS penetration such as 
high-dose cytarabine (Gaynon et al., 2000; Jabbour et al., 2010; Moricke et al., 2008). For 
reasons that are unknown, ALL patients require 2 to 2.5 years of chemotherapy to avoid 
relapse. This maintenance therapy consists of daily oral mercaptopurine and weekly oral 
methotrexate. Maintaining the maximum tolerated dose of mercaptopurine is an important 
prognostic factor, so drug doses are usually adjusted to maintain optimal leukocyte and 
neutrophil counts (Pui and Evans, 2006; Pui et al., 2004a; Relling et al., 1999; Stanulla and 
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Schrappe, 2009). As with frontline ALL therapy, treatment of relapsed ALL is guided by 
prognostic factors including time since first CR and cytogenetic features. Patients with high 
risk disease are treated with HSCT while others are treated with chemotherapy (Locatelli et 
al., 2012). 
General Principles of Cell Cycle Regulation and DNA Damage Repair 
Cell Cycle Regulation in Normal Cells 
The cell division cycle is the process by which cells replicate DNA and segregate 
duplicated chromosomes into two cells. Traditionally, the cell cycle is divided into G1, S, G2, 
and M phases. Preparation for DNA synthesis occurs during a gap phase known as G1. Cells 
in G1 can enter a quiescent, non-dividing state designated as G0 or pass the restriction point 
and commit to complete cell division (Bertoli et al., 2013). Cells replicate DNA in S phase 
and then enter a second gap, G2, during which preparation for mitosis occurs. In mitosis, or 
M phase, sister chromatids are separated, and cytoplasm is divided to form two daughter 
cells. 
Progression through the cell cycle is regulated by the cyclin-dependent kinase (CDK) 
family of serine/threonine kinases (Geenen and Schellens, 2017). CDK protein levels remain 
stable throughout the cell cycle, and the activity of specific CDK proteins is regulated in part 
by the differential expression of cyclin binding partners (Vermeulen et al., 2003). Three D-
type cyclins (D1, D2, and D3) bind to CDK4 and CDK6 in early G1. In contrast to other 
cyclins, cyclin D is continually expressed as long as cells have growth factor stimulation 
(Donjerkovic and Scott, 2000). Cyclin D-CDK4/6 phosphorylates the retinoblastoma (Rb) 
family of proteins which consists of pRb, p107, and p130 (Donjerkovic and Scott, 2000). Rb 
12 
 
proteins are further phosphorylated at the G1-S transition by cyclin E-CDK2 (Satyanarayana 
and Kaldis, 2009). Hypophosphorylated Rb binds to and inhibits the function of E2F 
transcription factors. When phosphorylated by cyclin-CDK complexes, Rb releases E2F 
proteins, resulting in expression of genes required for DNA synthesis (Sherr and Roberts, 
1999). Cyclin A-CDK2 promotes S phase progression by phosphorylating proteins required 
for DNA replication such as DNA polymerase α, DNA polymerase δ, and proliferating cell 
nuclear antigen (PCNA). Cyclin A-CDK2 also limits DNA replication to once per cell cycle 
by phosphorylating and promoting the nuclear export of CDC6 thus preventing its 
localization with the preinitiation complex (Woo and Poon, 2003). CDK1, also known as 
Cdc2, complexes with cyclin A in late G2 to promote entry into mitosis and with cyclin B 
during M phase to ensure progression through mitosis (Vermeulen et al., 2003). Cyclin B-
CDK1 activity is necessary for centrosome separation, nuclear envelope degradation, 
chromosome condensation, and spindle assembly. Cyclin B-CDK1 also enhances the activity 
of anaphase-promoting complex/cyclosome (APC/C) which targets mitotic proteins, 
including cyclin B, for proteolytic degradation. This, in turn, inactivates CDK1 which allows 
for mitotic exit (Nigg, 2001).  
In addition to regulation by cyclin binding, CDK activity is regulated by a number of 
other mechanisms. Phosphorylation of CDKs on specific threonine residues by cyclin H-CDK7 
which form CDK-activating kinase (CAK) induces a conformation change that enhances cyclin 
binding. (Fisher and Morgan, 1994; Morgan, 1995). CDK proteins can also be inhibited by 
phosphorylation, and these events will be described in detail in the following section. Another 
common inhibitory mechanism is the binding of CDKs alone or CDK-cyclin complexes by 
CDK inhibitory proteins (Figure 1.1). CDK inhibitory proteins are divided into two families. 
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The INK4 family consists of p16INK4a, p15INK4b, p18INK4c, and p19INK4d. INK4 proteins bind to 
CDK4 and CDK6 and prevent association with cyclin D. When INK4 proteins bind CDK4/6, 
unbound cyclin D is degraded, pRb remains in a hypophosphorylated state, and cells arrest in 
G1 phase (Kim and Sharpless, 2006; Roussel, 1999). The Cip/Kip family of CDK inhibitory 
proteins consists of p21WAF1/Cip1, p27Kip1, and p57Kip2. These proteins bind to and inhibit cyclin 
D-, E-, A-, and B-CDK complexes (Besson et al., 2008). p21 expression is regulated by P53, 
although P53-independent mechanisms of p21 activity have been described (Nakayama, 1998). 
p21 binds to cyclin-CDK complexes to promote cell cycle arrest in G1 (Besson et al., 2008). 
This protein can also halt DNA replication by binding to PCNA (Vermeulen et al., 2003). In 
contrast to p21, p27 accumulates in quiescent cells and is degraded as cells resume 
proliferation. p57 is vital to cell cycle regulation during embryonal development (Besson et 
al., 2008). 
DNA Damage Repair in Normal Cells 
DNA damage can occur from endogenous or exogenous insults and must be repaired 
to avoid loss of genetic information or transmission of mutations to daughter cells. Insults to 
DNA include single- and double-strand breaks, intrastrand crosslinks, DNA-protein 
crosslinks, and base modifications (Hosoya and Miyagawa, 2014). Various strategies exist to 
repair each type of damage. Here, the primary mechanisms of double- and single-strand 
break repair will be described. The first step in the DNA damage response (DDR) is 
recognition of DNA damage by sensor proteins. Signal transducer proteins link DNA damage 
recognition with the activation of effector pathways that include DNA damage repair and cell 
cycle arrest (Houtgraaf et al., 2006). The type of DNA damage incurred determines which 





Figure 1.1. The cell cycle is regulated by CDKs, cyclins, and CDK inhibitory proteins. 
The cell cycle is divided into G1, S, G2, and M phases. Cyclin D isoforms bind to CDK4 and 
CDK6 to promote progression through G1. Cyclin E-CDK2 promotes transition from G1 to S 
phase. Cyclin A interacts with CDK2 and CDK1 to regulate progression through S phase and 
G2 phase, respectively. Cyclin B/CDK1 promotes entry into mitosis. The INK4 family binds 
to CDK4 and CDK6 to promote cell cycle arrest in G1. The Cip/Kip family binds to cyclin-
CDK complexes and primarily functions to regulate the G1/S transition. Adapted from (Shah 













damage, others can be activated in response to several types of DNA damage. 
DNA double strand breaks are recognized by the Ku70/Ku80 heterodimer or by the 
MRE11-RAD50-NBS1 (MRN) complex (Branzei and Foiani, 2008). Double strand break 
recognition by Ku70/Ku80 leads to DNA repair via non-homologous end-joining (NHEJ) 
(Figure 1.2). In this pathway, the Ku heterodimer recruits DNA-dependent protein kinase 
catalytic subunit (DNA-PKCS). DNA-PKCS phosphorylates proteins including Artemis and 
DNA polymerases which process the DNA ends. The DNA ends are then ligated by DNA 
ligase IV/XRCC4 complex (De Lorenzo et al., 2013). NHEJ is an error-prone repair 
pathway. Nucleotides at each end of the DNA break are often lost prior to ligation which can 
lead to mutations (Lieber et al., 2003). NHEJ can also result in chromosomal translocations if 
ligation occurs between breaks of two different chromosomes (Hosoya and Miyagawa, 
2014).  
Alternatively, double strand breaks can be recognized by the MRN complex and 
repaired by homologous recombination (HR). HR consists of three major steps (Figure 1.2). 
The first step, double-strand break (DSB) end resection, consists of DSB end processing by 
the MRN complex, CtIP, and MRE11 to form a 3’ single-strand overhang tail (Michl et al., 
2016). This single-strand DNA is coated and stabilized by replication protein A (RPA). The 
second step of HR, strand invasion, requires Rad51 foci. Rad51 foci assembly is largely 
mediated by ataxia telangiectasia mutated (ATM) kinase. The MRN complex recruits ATM 
resulting in ATM autophosphorylation and subsequent dissociation of inactive dimers into 
catalytically active monomers (Roos and Kaina, 2013). Activated ATM phosphorylates a 
number of proteins including histone H2AX, MDC-1, PALB2, and BRCA1. PALB2 binds to 





Figure 1.2. A simplified overview of double-strand break repair by HR and NHEJ. 
Double-strand breaks can be repaired by HR or NHEJ. HR consists of three steps. 1) DSB 
end-processing forms a 3’ overhang tail which is coated by RPA. 2) BRCA1, PALB2, and 
BRCA2 facilitate Rad51 foci formation. This allows strand invasion to occur. Many proteins 
in this process are activated by ATM. 3) Once recombination is complete, the double 
Holliday junction is resolved. Alternatively, DSBs can be repaired by NHEJ. In this pathway, 
Ku70/Ku80 recruits DNA-PKCS which phosphorylates Artemis and DNA ligases to process 
broken ends. The ends are then ligated by DNA ligase IV/XRCC4. Adapted from (Brochier 





and loading of Rad51 onto the 3’ overhang. After Rad51 foci are formed, the 3’ overhang tail 
invades homologous double-strand DNA which forms the template for DNA repair. Several 
proteins including Rad52, Rad54, and XRCC3 assist in strand invasion and subsequent 
recombination. In the third and final step of HR, the double Holliday junction formed after 
DNA synthesis is resolved by resolvases such as GEN1 or MUS81-EME1 (Michl et al., 
2016). 
Repair of DNA single-strand breaks (SSBs) occurs in four steps. First, SSBs are 
recognized by the poly(ADP-ribose) polymerase (PARP) family of proteins which add chains 
of poly(ADP-ribose) to itself and other proteins to promote DNA repair (D'Amours et al., 
1999). SSB termini are often modified and must be restored to 3’-hydroxyl and 5’-phosphate 
moieties. The proteins that accomplish SSB end processing vary depending on the terminal 
modifications present (Caldecott, 2008; McKinnon and Caldecott, 2007). Once end 
processing is complete, missing nucleotides are replaced. Single nucleotide insertion is 
accomplished by DNA polymerase β while insertion of multiple nucleotides is mediated by 
FEN-1. Finally, DNA ligation is accomplished by DNA ligase I or DNA ligase IIIα 
(McKinnon and Caldecott, 2007). Exposed single strand DNA is coated by RPA which 
results in recruitment and activation of the ATM and RAD3-related (ATR) kinase. Single 
strand DNA can occur as a result of replication stress, end resection of double strand breaks, 
and DNA crosslinks. Thus, ATR is activated by many stimuli (Cimprich and Cortez, 2008). 
ATM and ATR are members of the phosphoinositide-3-kinase-related protein kinase family. 
While ATM and ATR are activated in response to different stimuli, these proteins regulate an 
overlapping set of substrates (Cimprich and Cortez, 2008). ATR promotes DNA damage 
repair and replication fork stability by phosphorylating substrates such as BRCA1, FANCD2, 
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and PCNA(Cimprich and Cortez, 2008). 
The Role of the Cell Cycle in the DNA Damage Response 
 Cell cycle arrest is a crucial component of the DDR as it prevents propagation of 
mutations to daughter cells or entry of cells with DNA damage into mitosis and subsequent 
mitotic catastrophe. Many of the same proteins that regulate DNA damage repair also initiate 
cell cycle arrest. ATM, the master regulator of HR, and ATR, a major regulator of SSB 
repair, initiate cell cycle arrest through the phosphorylation of CHK2 and CHK1, 
respectively (Branzei and Foiani, 2008). CHK1 and CHK2 promote cell cycle arrest by 
indirectly increasing inhibitory phosphorylation of CDK1 and CDK2 through mechanisms 
that will be described in the following section. Cell cycle arrest in response to DNA damage 
can occur at one of three transition points in the cell cycle: the G1/S checkpoint, the intra-S 
phase checkpoint, or the G2/M phase checkpoint. The G1/S checkpoint functions to block S-
phase entry and initiation of DNA replication. At this checkpoint, ATM activates CHK2 
which results in inactivation of cyclin E/CDK2 (Bose et al., 2014). ATM also phosphorylates 
P53 and murine double minute homolog 2 (Mdm2) at this checkpoint. This leads to elevated 
P53 levels which further promotes cell cycle arrest by elevating transcription of CDKN1A, 
the gene encoding p21 (Roos and Kaina, 2013). The intra-S phase checkpoint occurs in 
response to replication stress or DNA damage incurred during S phase and functions to slow 
DNA replication. ATM/CHK2 and ATR/CHK1 promote decreased activity of cyclin 
E/CDK2 and cyclin A/CDK2 complexes (Bose et al., 2014). The G2/M checkpoint prevents 
mitotic entry of cells that have accumulated DNA damage in G2 phase. Since the intra-S 
phase checkpoint promotes cell cycle slowing rather than cell cycle arrest, the G2/M 
checkpoint is also crucial in preventing mitosis in cells that have incurred DNA damage in 
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earlier cell cycle phases but have avoided arrest (Bose et al., 2014). The G2/M checkpoint is 
activated by ATR/CHK1-mediated inhibition of CDK1 and is maintained by increased 
activity of P53 (Bose et al., 2014).  
 The cell cycle phase is an important determinant of which DNA repair pathway a cell 
employs to repair incurred DNA damage, particularly in the context of DSBs. For example, 
DSBs are typically repaired by NHEJ in G1 and early S phase since homologous templates 
are unavailable. Once DNA has been replicated, sister chromatids are available for 
homologous templates, thus DSBs are repaired via HR (Branzei and Foiani, 2008). 
Furthermore, CDK activity can enhance or diminish the activity of DDR proteins to promote 
one pathway over another. Indeed, Rad51 foci formation and coating of single-strand DNA 
with RPA are impaired upon CDK inhibition with roscovitine (Jazayeri et al., 2006). CDKs 
phosphorylate CtIP to promote its interaction with BRCA1, an event important in promoting 
HR over NHEJ (Branzei and Foiani, 2008). Finally, CDK1 can also impair HR via inhibitory 
phosphorylation of BRCA2. These differing effects of CDK1 on various proteins in the HR 
pathway suggest CDKs could be required to initiate HR and generate 3’ overhang tails, but 
checkpoint activation and CDK inhibition could be necessary for later steps in HR to occur 
(Branzei and Foiani, 2008). 
Dysregulation of the Cell Cycle and DNA Damage Response in Cancer 
 Unrestrained proliferation and genomic instability are hallmarks of cancer that are 
mediated by direct or indirect dysregulation of cell cycle proteins (Malumbres and Barbacid, 
2009). Perhaps the best example of this is mutation of TP53 which occurs in over 50% of 
cancers and is associated with worse outcomes and response to therapy compared with TP53 
wild-type tumors (Vermeulen et al., 2003).  Additionally, wild-type TP53 can be functionally 
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inactivated by overexpression of MDM2. Both events lead to reduced p21 levels and loss of 
G1/S checkpoint integrity. Alterations in RB1, CDKN2A, and CDC25A are often found in 
cancer and lead to unrestrained progression through the G1/S phase checkpoint. RB1 encodes 
pRb, the primary target of cyclin-CDK complexes in G1 phase. RB1 mutation leads to loss of 
negative regulation of E2F transcription factors. Some member of the Rb pathway is 
dysregulated in roughly 90% of human malignancies highlighting the importance of this 
pathway in preventing unrestrained proliferation (Hall and Peters, 1996). Mutation or 
hypermethylation of CDKN2A occurs in 20-30% of ALL cases and results in reduced levels 
of p16INK4a (Hall and Peters, 1996). CDC25A encodes a phosphatase that desphorylates and 
activates CDKs. This gene is particularly important in the G1/S transition and is frequently 
overexpressed in cancer (Nilsson and Hoffmann, 2000). Alterations in genes encoding CDKs 
or cyclin occur less frequently than changes in genes that encode CDK inhibitory proteins or 
downstream CDK effectors. CDK1 and CDK2 are overexpressed in some colon 
adenocarcinomas, and mutations in CDK4 and CDK6 that prevent CDK inhibitory protein 
binding have been identified (Vermeulen et al., 2003). A translocation involving CCND1, the 
cyclin D1 gene, occurs in some B-cell cancers such as mantle cell lymphoma. Also, cyclin E 
is overexpressed in some AML and ALL cases (Malumbres and Barbacid, 2009; Vermeulen 
et al., 2003). 
 A number of genes essential for DNA damage repair are either activated or 
inactivated in cancer. DNA-PKcs is overexpressed in radiation-resistant tumors. and 
overexpression of RAD51, BRCA1, and PARP1 occurs in some malignancies resistant to 
chemotherapy (Hosoya and Miyagawa, 2014). Defects in MSH2, a gene required for 
mismatch repair and DSB repair, is associated with childhood leukemias including ALL 
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(Holt et al., 2009). In AML, common genetic events such as PML/RARα gene fusions and 
FLT3-ITD mutations are associated with defects in the NHEJ pathway (Esposito and So, 
2014). Further underscoring the necessity of an intact DNA damage response is the 
observation that mutations in DDR proteins result in syndromes such as ataxia-telangiectasia 
(ATM mutations), Seckel (ATR mutations), and Li-Fraumeni (CHEK2 and TP53 mutations) 
which predispose patients to cancer (Malumbres and Barbacid, 2009). 
WEE1 Tyrosine Kinase 
Discovery of WEE1 
WEE1 was originally identified in Saccharomyces pombe in 1975 by Paul Nurse 
(Nurse, 1975). S. pombe divides at a constant cell length, so identification of shorter cells in a 
pool of temperature-dependent mutants suggested mutation in a gene lead to premature cell 
division. The Scottish term “wee” was given to the cloned gene to indicate the small cell size 
that occurred upon gene mutation and in recognition of the University of Edinburgh where 
this gene was discovered (Nurse, 2004). Later work determined that the wee1+ gene encoded 
a dual-specificity kinase that is a dose-dependent inhibitor of mitosis. The gene product was 
determined to regulate cdc2+, the ortholog of human CDK1, and oppose cdc25+, a positive 
regulator of mitosis (Russell and Nurse, 1987). Paul Nurse was ultimately awarded a Nobel 
prize for this work in 2001 (De Witt Hamer et al., 2011). The human WEE1 gene was 
identified in 1991 by its ability to rescue wee1+ mutants in fission yeast in 
transcomplementation assays. The human gene is located on 11p15.3-11p15.1 and consists of 
a central kinase domain and N- and C-terminal regulatory domains (Igarashi et al., 1991; 
Taviaux and Demaille, 1993). The kinase domain of human WEE1 shares 29% homology 
with the S. pombe wee1+ gene, but the C-terminal and N-terminal domains of the human 
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genes share no homology with the fission yeast counterpart (Igarashi et al., 1991). In contrast 
with S. pombe wee1+ which phosphorylates both serine and tyrosine residues, in vitro kinase 
assays indicate that human WEE1 is a tyrosine-specific kinase (Parker and Piwnica-Worms, 
1992). 
The Function of WEE1 
WEE1 is a key regulator of the G2/M phase checkpoint that prevents untimely 
mitosis by inhibiting CDK1 via phosphorylation at tyrosine 15. WEE1 is primarily a nuclear 
protein, and it functions to ensure the completion of DNA replication prior to initiation of 
mitosis (Heald et al., 1993). MYT1 can also inhibit CDK1 by phosphorylation at threonine 
14. However, MYT1 is membrane-bound and functions to inhibit CDK1 activity in the 
cytoplasm (Booher et al., 1997). In addition to inhibiting CDK1 by phosphorylation, MYT1 
also binds and sequesters cyclin B1/CDK1 in the cytoplasm to prevent its nuclear import 
(Wells et al., 1999). WEE1 and MYT1 are opposed by the CDC25 family of phosphatases 
which activates CDK1 by dephosphorylation at threonine 14 and tyrosine 15 (Lindqvist et 
al., 2009). Thus, cyclin B/CDK1 nuclear activity is largely a balance between WEE1 and 
CDC25 activity. In the absence of DNA damage, WEE1 is phosphorylated at serine 123 by 
cyclin B/CDK1 at the G2/M transition. This phosphorylation event promotes further WEE1 
phosphorylation at serine 121 by CK2 and at serine 53 by polo-like kinase 1 (PLK1). Each of 
these phosphorylation events promotes WEE1 recognition by F-box protein β-TrCP, a 
component of the SCF-β-TrCP E3 ubiquitin ligase, which targets WEE1 for proteasomal 
degradation (Perry and Kornbluth, 2007). In parallel, PLK1 phosphorylates CDC25C to 
promote nuclear localization (Lindqvist et al., 2009; Toyoshima-Morimoto et al., 2002). 




In addition to its role in regulating mitotic entry, WEE1 similarly regulates DNA 
replication by inhibiting CDK2 via phosphorylation at tyrosine 15. WEE1 limits CDK 
activity in S-phase to regulate initiation of replication. Inhibition or genetic depletion of 
WEE1 results in increased replication origin firing leading to nucleotide shortage, replication 
fork slowing, and DNA damage induction (Beck et al., 2012). This DNA damage occurs in 
S-phase cells in the absence of other DNA damaging insults and independent of premature 
mitotic entry (Dominquez-Kelly et al., 2011). This DNA damage is associated with elevated 
single-strand DNA, an intermediate of replication-associated lesions (Beck et al., 2010). 
Regulation of DNA replication by WEE1 is dependent on the Mus81-Eme1 endonuclease as 
knockdown of either component of the endonuclease restores normal S-phase progression. 
WEE1 physically associates with the Mus81-Eme1 endonuclease, but whether it regulates the 
endonuclease directly or indirectly through CDK1/2 is unknown (Dominquez-Kelly et al., 
2011). 
In addition to its role in directly regulating CDK1 and CDK2 activity. WEE1 
indirectly influences HR, deoxyribonucleotide (dNTP) production, and cytokinesis (Heijink 
et al., 2015; Krajewska et al., 2013; Pfister et al., 2015). Inhibition of WEE1 causes aberrant 
activation of CDK1 in interphase cells. This increased CDK1 activity leads to inhibitory 
BRCA2 phosphorylation and impaired HR in cells exposed to ionizing radiation (Krajewska 
et al., 2013). Aberrant CDK activity also increases phosphorylation of RRM2, a subunit of 
ribonucleotide reductase necessary for dNTP synthesis. This phosphorylation targets RRM2 
for degradation by the SCF-cyclin F ubiquitin ligase and results in reduced dNTP pools. 
Thus, WEE1 also functions to maintain dNTP pools for necessary for DNA replication 
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(Pfister et al., 2015). In late mitosis, WEE1 functions to couple CDK1 activity with cyclin B 
degradation. In the absence of WEE1, CDK1 remains active after cyclin B is degraded. This 
results in impaired karyokinesis and cytokinesis and increased numbers of tetraploid cells 
(Heijink et al., 2015). WEE1 was recently determined to directly phosphorylate histone H2B 
at tyrosine 37 upstream of the HIST1 gene cluster. This functions to inhibit histone gene 
transcription at the end of S-phase, thus maintaining the appropriate nucleosome to DNA 
ratio (Mahajan et al., 2012). However, the functional consequences of abrogation of this 
phosphorylation event have not been studied.  
In response to DNA DSBs, ATM activates CHK2 which phosphorylates CDC25C to 
promote 14-3-3σ binding and nuclear export. Reduced nuclear CDC25C results in unopposed 
WEE1 in the nucleus leading to elevated inhibitory phosphorylation of CDK1 and/or CDK2 
and cell cycle arrest. Replication stress and exposed singe-strand DNA activates ATR which, 
in turn, phosphorylates and activates CHK1. CHK1 phosphorylates WEE1 at serine 642 in 
the C-terminal regulatory domain. This phosphorylation promotes WEE1 binding to 14-3-3β 
which enhances protein stability and activity (Perry and Kornbluth, 2007). Like CHK2, 
CHK1 also phosphorylates CDC25C and promotes its nuclear export. Together, these events 
promote increased inhibitory phosphorylation of CDK1 and/or CDK2 and arrest at the S- or 
G2/M-phase checkpoint in response to DNA damage (Figure 1.3) (Perry and Kornbluth, 
2007). 
WEE1 Expression in Cancer 
 As described in the previous section, a number of G1/S checkpoint mediators are 
frequently mutated in cancer. Thus, many cancer cells are uniquely reliant on an intact 




Figure 1.3. The role of WEE1 in G2/M checkpoint activation. Exposed single-strand 
DNA occurs in response to DNA DSB end processing and replication stress. Single-strand 
DNA leads to activation of ATR which phosphorylates CHK1. CHK1 phosphorylates WEE1 
to promotes its stability and activity. CHK1 also phosphorylates CDC25C phosphatase and 
targets it for nuclear export. Together these events promote increased inhibitory 













(Matheson et al., 2016a). Consistent with this, WEE1 is overexpressed in a number of 
malignancies including hepatocellular carcinoma, luminal and HER-2 positive breast cancer, 
cervical cancers, vulvar squamous cell carcinoma, lung cancer, glioblastoma, diffuse intrinsic 
pontine glioma, medulloblastoma, leukemia, malignant melanoma, high-grade gastric cancers 
and ovarian cancers (E. et al., 2009; GI et al., 2012; Harris et al., 2014; Kim et al., 2016; 
Magnussen et al., 2013; Mir et al., 2010; Mueller et al., 2014; Music et al., 2016; Porter et al., 
2012; Slipicevic et al., 2014; T. et al., 2003; Tibes et al., 2012). Increased WEE1 expression 
correlates with lymph node metastasis and poorly differentiated tumors in vulvar squamous 
cell carcinoma and with a metastatic phenotype and poor disease-free survival in melanoma 
(GI et al., 2012; Magnussen et al., 2013). High WEE1 expression is associated with lymph 
node metastases and reduced probability of survival in gastric cancer (Kim et al., 2016). 
WEE1 expression was also found to be elevated in relapsed ovarian cancer after 
chemotherapy compared with tumors at diagnosis. This study found WEE1 expression to be 
an independent prognostic marker in ovarian cancer (Slipicevic et al., 2014). Furthermore, 
the catalogue of somatic mutations in cancer (COSMIC) database reports less than 1% of 
cancers possess mutations in the WEE1 gene, suggesting that cancer cells may rely on 
unmutated WEE1 to maintain G2/M checkpoint integrity. Conversely, others have found that 
reduced WEE1 expression correlates with higher recurrence rates and poor prognosis in non-
small cell lung cancer (Yoshida et al., 2004). Low or absent WEE1 was also identified in 
primary prostate cancer samples and colon cancer cell lines (Backert et al., 1999; Kiviharju-
af Hallstrom et al., 2007). Some tumors with reduced WEE1 expression also have elevated 
p21 expression, indicating tumors that maintain other intact checkpoint controls may be less 
reliant on the function of WEE1 to avoid mitotic catastrophe (Backert et al., 1999). Thus, 
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while WEE1 expression is associated with more aggressive tumors in some circumstances, 
this is likely dependent on the genetic background and types of treatment the tumor has been 
exposed to. 
Small-Molecule Inhibitors of WEE1 
 As a key regulator of the G2/M checkpoint, WEE1 is a promising target to prevent 
DNA damage-induced checkpoint activation and promote mitotic catastrophe of cells with 
accumulated DNA damage. As such, a number of small-molecule WEE1 inhibitors have 
been developed (Table 1.1). The first identified small-molecule WEE1 inhibitor was a 
pyridopyrimidine molecule, PD0166285. The molecule was identified in a screen of 
molecules that increased phosphorylation of histone H1, a substrate of CDK1. PD0166285 is 
an ATP-competitive inhibitor that inhibits WEE1 with an IC50 of 24 nM. However, this drug 
inhibits other proteins with IC50 values in the nanomolar range including MYT1, CHK1, c-
Src, epidermal growth factor rector (EGFR), fibroblast growth factor receptor-1 (FGFR1), 
and platelet-derived growth factor receptor β (PDGFRβ) (Matheson et al., 2016a; Wang et 
al., 2001). A number of other molecules have been synthesized based on the parent structure 
of PD0166285, but specificity for WEE1 was not achieved (Palmer et al., 2005). Next, the 
group that identified PD0166285 found PD0407824 to inhibit WEE1 while performing a 
high-throughput screen to identify inhibitors of the protein kinase C family. This inhibitor 
was more specific for WEE1 (IC50 = 97 nM) than for c-Src (IC50 > 50 uM) but also 
maintained specificity for CHK1 (IC50 = 47 nM) (Palmer et al., 2006). Modifications of the 
PD0407824 molecule lead to the discovery of molecules named WEE1 inhibitor and WEE1 
inhibitor II. Although these drugs were selective for WEE1 over CHK1, further development 
has been limited, possibly due to broad-spectrum kinase inhibitory activity (Matheson et al., 
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2016a; Palmer et al., 2006). Another high-throughput screen was performed to identify 
inhibitors of WEE1. Information from structure-activity relationship assays was used to 
modify the initial hits of the screen, and this lead to the development of AZD1775 (formerly 
known as MK-1775) (Hirai et al., 2009). AZD1775 is a potent, ATP-competitive inhibitor of 
WEE1 (IC50 = 5.2 nM) with an in vivo half-life of 9-12 hours in mice (Geenen and Schellens, 
2017; Hirai et al., 2009). In a screen of over 200 kinases, 1 uM AZD1775 inhibited 8 kinases 
by greater than 80% including the Src family kinase YES1 (IC50 = 14 nM). AZD1775 
inhibited the other 7 kinases with IC50 values 10-fold greater than that of WEE1, but the 
identity of these kinases was not disclosed (Hirai et al., 2009). Using a kinome interaction 
study, others have named ABL1, LCK, LRRK2, TNK2, and SYK as targets of AZD1775 
with IC50 values less than 1 uM (Matheson et al., 2016a). A carboxylate methyl-ester 
derivative of AZD1775 designated CJM061 was recently demonstrated to uncouple WEE1 
inhibition from cell toxicity. Despite reduced single-agent toxicity, this compound maintains 
synergy with cisplatin. Further investigation of this compound is required, but this data 
suggests some of the cytotoxicity of AZD1775 could be due to off-target effects (Matheson 
et al., 2016a; Matheson et al., 2016b). 
Preclinical Studies of WEE1 Inhibition 
 Because of its role as a checkpoint mediator, inhibition of WEE1 has primarily been 
studied in combination with DNA damaging agents. Treatment with PD0166285 or siRNA 
knockdown of WEE1 abrogated G2/M-phase arrest and enhanced apoptosis in lung cancer 
cells exposed to gamma radiation (Li et al., 2002), glioblastoma treated with temozolomide 
or ionizing radiation (Mir et al., 2010), osteosarcoma cells exposed to radiation 
(PosthumaDeBoer et al., 2011), colon cancer treated with radiation (Wang et al., 2001), and  
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Table 1.1. Small-molecule WEE1 inhibitors. Adapted from (Matheson et al., 2016a). 



































































cervical cancer cells treated with doxorubicin (Wang et al., 2004). The sensitization to 
ionizing radiation accomplished by PD0166285 in colon, ovarian, and lung cancer cell lines 
was more effective in P53-deficient cell lines than in P53-intact cells consistent with the 
hypothesis that cells with loss of G1/S-phase checkpoint integrity have increased reliance on 
the G2/M-phase checkpoint to maintain genomic integrity when faced with genotoxic insults 
(Li et al., 2002; Wang et al., 2001). Although results in cells treated with PD0166285 are 
consistent with results obtained in cells with WEE1 knockdown, it must be noted that the 
numerous off-target effects of PD0166285 limit conclusions of the effects of WEE1 
inhibition alone in sensitizing cells to DNA damaging agents. Thus, the majority of studies of 
pharmacologic inhibition of WEE1 have been performed with AZD1775 as this drug has 
reduced off-target effects. A summary of pre-clinical studies with AZD1775 in both 
combination and single-agent therapy can be found in Table 1.2. Consistent with the role of 
WEE1 in ensuring faithful DNA replication, AZD1775 treatment enhanced the efficacy of 
anti-metabolite chemotherapies including 5-fluorouracil in gastric cancer (Kim et al., 2016), 
gemcitabine in colon adenocarcinoma and non-small cell lung cancer (NSCLC) (Hirai et al., 
2009), pememtrexed in NSCLC (Van Linden et al., 2013), and 5-fluorouracil in colon 
adenocarcinoma (Hirai et al., 2010). AZD1775 enhanced apoptosis in colorectal 
adenocarcinoma cells treated with topoisomerase inhibitors doxorubicin or camptothecin by 
abrogating the G2/M-phase DNA damage checkpoint (Hirai et al., 2010). AZD1775 
synergized with cisplatin in medulloblastoma cell lines and increased the sub-G1 population 
in ovarian cancer cell lines with TP53 knockdown treated with cisplatin or carboplatin 
(Harris et al., 2014; Hirai et al., 2009). Pancreatic ductal adenocarcinoma cells lacking 
mutations in key DDR genes, designated as DDR-proficient cells, were sensitive to  
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Table 1.2. Summary of pre-clinical studies with AZD1775 
Study/Author Year Cancer Type Model Therapy 





Hirai et al. 2009 Colon Adenocarcinoma, 
NSCLC 









Hirai et al. 2010 Colon Adenocarcinoma, 
Breast Cancer 













Harris et al. 2014 Medulloblastoma In Vitro Cisplatin 
Lal et al. 2016 Pancreatic Ductal 
Adenocarcinoma 
In Vitro Mitomycin C, 
Oxaliplatin 


















Karnak, et al. 2014 Pancreatic Ductal 
Adenocarcinoma 





Bridges et al. 2011 NSCLC, Colon 
Adenocarcinoma, Breast 
Cancer, Prostate Cancer 




Cuneo et al. 2016 Hepatocellular Carcinoma In Vitro Ionizing 
Radiation 









Guertin, et al. 2013 NSCLC, Ovarian Cancer, 
Melanoma 





AZD1775 combined with DNA cross-linking agents mitomycin C or oxaliplatin while cells 
possessing mutations in these genes, named DDR-deficient cells, were not (Lal et al., 
2016).Combined treatment with AZD1775 and paclitaxel, a mitotic spindle inhibitor, reduced 
cell viability and enhanced DNA damage induction and apoptosis in gastric cancer cell lines 
(Kim et al., 2016). High-grade glioma cell lines treated with AZD1775 and radiation 
demonstrated increased DNA damage induction and decreased clonogenic survival compared 
with cells receiving radiation alone (Mueller et al., 2014). Likewise, P53-deficient colon, 
lung, breast, and prostate cancer cell lines were sensitive to AZD1775 in combination with 
radiation therapy (Bridges et al., 2011). Treatment with AZD1775 produced some 
radiosensitization in pancreatic ductal adenocarcinoma cell lines, but AZD1775 and the 
PARP1/2 inhibitor olaparib together produced significant radiosensitization (Karnak et al., 
2014). 
  Beyond in vitro models of solid tumors, AZD1775 has been widely studied as a 
method of enhancing chemotherapy and radiation in xenograft models. AZD1775 combined 
with 5-fluorouracil or paclitaxel in gastric cancer xenografts (Kim et al., 2016), gemcitabine 
in colon cancer models (Hirai et al., 2009), carboplatin for cervical cancer xenografts (Hirai 
et al., 2009), and cisplatin for ovarian cancer xenografts (Hirai et al., 2009) all reduced tumor 
volumes with minimal added toxicity. AZD1775 combined with 5-fluorouracil in colon 
adenocarcinoma xenografts (Hirai et al., 2009) and with gemcitabine in patient-derived P53-
deficient pancreatic cancer xenografts (Rajeshkumar et al., 2011) resulted in premature 
mitosis and significant tumor regression. Combined treatment with AZD1775, olaparib, and 
ionizing radiation resulted in delayed tumor volume doubling and lead to a complete 
regression in 20% of tumors in pancreatic xenograft models (Karnak et al., 2014). 
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In addition to enhancing the efficacy of genotoxic agents in solid tumor models, 
inhibition of WEE1 via AZD1775 also has combinatorial activity with cytarabine and 
vincristine in AML and ALL cell lines, murine models, and patient samples. In a genome-
wide shRNA screen, Porter et al. identified WEE1 as a target to enhance the anti-tumor 
effects of Ara-C in AML cells. AZD1775 synergized with Ara-C in AML cell lines and 
inhibited proliferation and induced apoptosis in AML patient samples. Ara-C induced an S-
phase arrest that was abrogated with AZD1775 treatment (Porter et al., 2012). Thus, this 
work suggests that inhibition of WEE1 might sensitize cells to anti-metabolite 
chemotherapeutics by abrogating the intra-S phase checkpoint. Tibes et al. identified WEE1 
as a target in cytrabine-treated AML cells in a similar screen. Treatment of AML, ALL, and 
chronic myeloid leukemia (CML) cell lines with AZD1775 enhanced sensitivity to Ara-C up 
to 97-fold (Tibes et al., 2012). In T-ALL cells, AZD1775 acts synergistically with cytarabine 
and vincristine but not with doxorubicin. AZD1775 enhances the effects of cytarabine by 
promoting apoptosis over DNA damage repair. AZD1775 enhanced the anti-proliferative 
effect of Ara-C in diagnosis and relapse cells derived from the same patient indicating that 
this combination might be effective in relapse patients who have previously been treated with 
multi-agent chemotherapy (Ford et al., 2015). In addition to DNA damaging agents, 
AZD1775 has combinatorial activity with pan-HDAC inhibitors vorinostat and SBHA in P53 
wild-type and deficient AML cell lines. WEE1 inhibition results in replication stress and 
activation of the ATR/CHK1 pathway, and HDAC inhibition prevents CHK1 activation and 
increases apoptosis (Zhou et al., 2015). 
Some studies have identified AZD1775 as an effective monotherapy in cancer. 
AZD1775 treatment promoted unscheduled mitotic entry in P53-deficient and -proficient 
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sarcoma cell lines and increased apoptosis in patient-derived bone and soft tissue sarcoma 
samples. AZD1775 also enhanced the effects of gemcitabine in this study (Kreahling et al., 
2013). AZD1775 treatment lead to DNA DSBs during S-phase in cell lines from multiple 
cancers including ovarian clear cell carcinoma, melanoma, and NSCLC. AZD1775 treatment 
yielded a 50% reduction in tumor volume in a NSCLC xenograft model (Guertin et al., 
2013). AZD1775 monotherapy induced apoptosis and cell cycle arrest in gastric cancer cell 
lines expressing high levels of WEE1, but AZD1775 combined with 5-fluorouracil or 
paclitaxel was a more effective strategy (Kim et al., 2016). Single-agent AZD1775 also has 
anti-tumor effects in cells lacking histone 3 lysine 36 (H3K36) trimethylation which can 
occur because of mutation of the histone, overexpression of histone demethylase KDM4A, or 
loss of tumor suppressor SETD2. Reduced H3K36 trimethylation results in reduced 
transcription of RRM2, a subunit of ribonucleotide reductase. As previously discussed, 
WEE1 inhibition results in RRM2 degradation and increased nucleotide consumption due to 
elevated replication initiation. Combined, these events lead to S-phase arrest and apoptosis 
(Pfister et al., 2015). Other in vivo studies have shown no anti-tumor effects of AZD1775 
monotherapy, but the drug was dosed below its maximum tolerated dose of 60 mg/kg twice 
per day (Matheson et al., 2016a). Thus, AZD1775 monotherapy might be an effective 
treatment in some cancers. 
AZD1775 was originally thought to be an effective sensitizing agent only in P53-
defective cells as these cells would have an inactive G1/S checkpoint and be more reliant on 
an intact G2/M checkpoint to avoid mitotic catastrophe. Some studies have confirmed 
selective sensitivity of AZD1775 and DNA damaging agents in P53-defective cells. Hirai et 
al. first reported that shRNA-mediated knockdown of p53 sensitized an ovarian cancer cell 
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line to AZD1775 in combination with gemcitabine, cisplatin, or carboplatin (Hirai et al., 
2009). This group later showed sensitization to AZD1775 combined with camptothecin, 
doxorubicin, 5-fluorouracil, mitomycin C, and pemetrexed in P53-deficient, but not P53-
proficient, colon cancer cells (Hirai et al., 2010). AZD1775 enhanced radiation therapy in 
colon, lung, breast, and prostate cancer cell lines with defective P53 but not in cell lines with 
functional P53 (Bridges et al., 2011). Conversely, others have reported that AZD1775 
sensitizes cells to DNA damaging agents independent of P53 functionality. AZD1775 
synergizes with cytarabine in both TP53 wild-type and mutant AML cells, and inhibition of 
endogenous P53 via expression of a dimerization domain of P53 (DDp53) construct does not 
enhance or abrogate this synergy (Van Linden et al., 2013). AZD1775 improves radiation 
therapy in high grade glioma cell lines and cisplatin in medulloblastoma cell lines 
independent of P53 status (Harris et al., 2014; Mueller et al., 2014). Cuneo et al. reported that 
AZD1775 abrogated the G2/M arrest induced by radiation in TP53 mutant, but not TP53 
wild-type hepatocellular carcinoma cell lines. However, AZD1775 enhanced radiation 
therapy due to overconsumption of nucleotides in both TP53 mutant and wild-type cells 
(Cuneo et al., 2016). One caveat to the reports of P53-independent sensitization via WEE1 
inhibition is many address TP53 mutation status or ability to increase p21 expression in 
response to DNA damage but fail to demonstrate integrity of the entire P53 pathway or other 
potential mechanisms of G1/S checkpoint inactivation (Geenen and Schellens, 2017). Some 
of these studies also lack proof that AZD1775-mediated sensitization is the result of WEE1 
inhibition alone and not of off-target effects of the drug. Despite these pitfalls, these reports 
do suggest that AZD1775 can be used to enhance chemotherapy or radiation in P53-
proficient cells in some contexts, and further work is warranted to understand why some P53-
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proficient cell lines respond to combination involving AZD1775 while others do not. 
Similarly, at least some drug combinations involving WEE1 inhibition appear to be context-
specific. For example, AZD1775 enhances the anti-proliferative effect of doxorubicin in 
colorectal adenocarcinoma cells but is antagonistic in T-ALL cells (Hirai et al., 2010; Van 
Linden et al., 2013). This cannot be explained by differences in P53 functionality since 
AZD1775 and doxorubicin were determined to be antagonistic in a TP53 mutant T-ALL cell 
line (Van Linden et al., 2013). Thus, further work is required to identify biomarkers to 
predict sensitivity to various combinations with AZD1775. Finally, the majority of pre-
clinical studies with AZD1775 have been performed in combination with non-targeted DNA 
damaging agents. Additional studies are required to determine if AZD1775 can enhance the 
anti-tumor effects of targeted agents. In Chapter III of this thesis, I demonstrate that 
AZD1775 can sensitize acute leukemia cells to the small-molecule PARP inhibitor olaparib. 
Clinical Studies of WEE1 Inhibition 
 There are currently 37 clinical studies listed on ClinicalTrials.gov (accessed May 
2017) for AZD1775 in a number of cancer types including glioblastoma, small cell lung 
cancer, platinum-resistant ovarian cancer, AML, metastatic colorectal cancer, and pancreatic 
adenocarcinoma. In the majority of studies, AZD1775 is combined with DNA damaging 
agents including cisplatin, cytarabine, paclitaxel, radiation therapy, gemcitabine, olaparib, 
carboplatin, and temozolomide. Six studies are examining AZD1775 as a single agent 
therapy. Most of these trials are in early phases, but some data from Phase I trials is 
available. A study of AZD1775 in monotherapy was completed to determine the safety, 
maximum-tolerated dose, and pharmacokinetics of the drug. The maximum-tolerated dose 
was 225 mg twice per day orally, 2.5 days per week for 2 weeks in a 21-day cycle. The most 
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common side effects were diarrhea and myelosuppression, and dose-limiting toxicities were 
supraventricular tachycardia and myelosuppression. One patient with head and neck cancer 
and another with ovarian cancer had partial responses. Both patients had BRCA1 mutations 
and neither had a TP53 mutation (Do et al., 2015b; Matheson et al., 2016a). A study of 
AZD1775 in monotherapy or in combination with gemcitabine, cisplatin, or carboplatin in 
advanced solid tumors was recently completed. The study consisted of 202 patients, and the 
most common tumor types were melanoma, ovarian cancer, breast cancer, colorectal cancer, 
and lung cancer (Do et al., 2015a). Five out of nine patients receiving single-agent AZD1775 
experienced a drug-related adverse event; however, these events were not dose limiting. In 
patients receiving one of the combination therapies, 19% experienced serious adverse events. 
The most common adverse events were hematologic toxicity, nausea/vomiting, diarrhea, and 
fatigue. A partial response was observed in 10% of patients, and 53% of patients had stable 
disease for a minimum of 6 weeks. Of the patients with a TP53 mutation, 21% had a partial 
response while 12% of TP53 wild-type patients experienced a partial response (Do et al., 
2015a).  
Resistance to Kinase Inhibitors 
 Kinases are necessary for nearly all processes that drive tumor initiation and 
progression including cell proliferation, metabolism, and survival. Kinase expression is often 
tissue specific, and kinases have well-characterized ATP binding, substrate binding, and 
regulatory domains that can be targeted by small-molecules. As such, kinases are attractive 
targets in cancer therapy and are the second largest drug target family (Barouch-Bentov and 
Sauer, 2011). However, despite promising results from preclinical and clinical studies, cancer 
cells usually develop resistance to kinase inhibitors. Drug resistance may be pre-existent 
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(intrinsic) or drug-induced (acquired). Intrinsic drug resistance can occur because of lack of 
addiction to the targeted kinase or differential drug metabolism. Acquired drug resistance can 
result from enhanced drug efflux, development of mutations that prevent drug binding, and 
activation of compensatory survival pathways (Sharma et al., 2010).  
Recent evidence points to changes in gene expression because of an altered epigenetic 
landscape as an important driver of drug resistance (Pribluda et al., 2015). Epigenetic 
changes that result in altered gene expression include DNA methylation at CpG dinucleotides 
and methylation, acetylation, and phosphorylation of histones (Glasspool et al., 2006). 
Proteins that regulate the epigenetic landscape are divided into three classes: proteins that 
write the marks (methyltransferases and acetyltransferases), proteins that erase the marks 
(histone demethylases and histone deacetylases (HDACs)), and proteins that read the marks 
(bromodomain and chromodomain proteins) (Pribluda et al., 2015). Histone demethylases 
and deacetylases have been identified as mediators of resistance to both kinase inhibitors and 
conventional chemotherapies (Figure 1.4). Sharma et al. reported that insulin growth factor-
1R (IGF-1R)-mediated upregulation of KDM5A, a histone 3 lysine 4 (H3K4) demethylase, 
regulates multi-drug resistance in NSCLC cells. Inhibition of IGF-1R or knockdown of 
KDM5A abrogated resistance to the EGFR inhibitor gefitinib and to cisplatin. HDACs 
complex with KDM5A and are necessary for KDM5A activity, and the group showed that 
pan-HDAC inhibition reduced H3K4 trimethylation and abrogated drug resistance. HDAC 
inhibition also prevented the emergence of drug resistance clones from cells that are sensitive 
to EGFR inhibition (Sharma et al., 2010). Similarly, Banelli et al. reported that HDAC 
inhibition or KDM5A knockdown abrogated resistance to temozolomide in glioblastoma 




Figure 1.4. Epigenetic mediators of drug resistance. A and B. Altered activity of 
epigenetic erasers, designated as scissors, contributes to drug resistance. Inhibition of 
HDACs (A right) or KDM5A demethylase (B right) can reverse resistance to gefitinib and 
cisplatin in NSCLC and to temozolomide in glioblastoma. C. BRD4 contributes to drug 
resistance partly by increasing expression of MYC. Inhibition of BRD4 reduced MYC levels 






molecules that do not target kinases. T-ALL cell resistance to γ-secretase inhibitors can be 
reversed by knockdown or inhibition of BRD4, a BET family bromodomain protein that 
binds acetylated histones. The MYC oncogene is a driver in T-ALL, and MYC expression is 
regulated by BRD4. Overexpression of MYC can partially reverse the effect of BRD4 
inhibition indicating that BRD4 mediated MYC overexpression is a key driver of γ-secretase 
inhibitor resistance in T-ALL cells (Knoechel et al., 2014). 
One study has attempted to identify mutations that would confer resistance to the 
WEE1 inhibitor AZD1775. To accomplish this, a functional genetic screen was performed in 
the near-haploid CML cell line KBM-7 by gene-trap insertional mutagenesis. Genes 
regulating the G1/S transition were preferentially mutated in cells surviving AZD1775 
treatment, and knockdown of CDK2, CUL1, or SKP2 induced resistance to WEE1 inhibition 
in KBM-7 cells and in breast and ovarian cancer cell lines. Knockdown of these genes did 
not alter the amount of DNA damage accumulated during S phase but restored G2 length 
which was shortened with AZD1775. This allowed cells adequate time to repair DNA 
damage prior to mitosis (Heijink et al., 2015). Mutation status of genes that regulate the G1/S 
transition could be informative in identifying patients who will benefit from WEE1 inhibition 
as a monotherapy, but it is not known whether mutation of these genes alters sensitivity to 
AZD1775 in combination with chemotherapy. Also, it is unknown whether mutation of these 
genes would be a mechanism of acquired resistance to AZD1775. In Chapter IV of this 
thesis, I address a mechanism of acquired resistance to AZD1775 in acute leukemia cells.  
Summary 
 While outcomes in AML and ALL have improved substantially in recent decades, the 
prognosis for patients who relapse or cannot tolerate standard chemotherapy regimens 
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remains poor. Therefore, novel therapies are needed for these groups of patients. WEE1 is a 
tyrosine kinase that inhibits CDK1 and CDK2 in response to DNA damage to promote cell 
cycle arrest and DNA damage repair. Consistent with a role in promoting survival in cells 
with DNA damage, inhibition of WEE1 via the small-molecule inhibitor AZD1775 enhances 
the anti-tumor effects of multiple chemotherapy agents by increasing DNA damage and/or 
promoting premature mitosis. Despite these promising results, the mechanism of 
combinatorial activity of AZD1775 and conventional chemotherapies is not well understood. 
Furthermore, studies examining AZD1775 combined with targeted agents are limited, and 
potential mechanisms of acquired resistance to AZD1775 are unknown. My dissertation 
seeks to address these deficiencies in order to provide a better understanding of WEE1 




MATERIALS AND METHODS 
Cell Culture 
Jurkat, Molm13, MV4;11, REH, and OCI-AML3 cell lines were generous gifts from 
the laboratories of Drs. Douglas Graham and James DeGregori. 32D cells were purchased 
from ATCC. Cell lines were DNA fingerprinted by multiplex PCR using the Profiler Plus or 
Identifier Kits (ABI) as previously described (Van Linden et al., 2013), and periodically 
tested for Mycoplasma by PCR. Cells were cultured in RPMI with 10% FBS and 
penicillin/streptomycin at 37oC in humidified air supplemented with 5% CO2 and maintained 
in culture for no longer than 2 months. WEHI3 conditioned media was added to the culture 
media at 10% as a source of IL-3 for 32D cells. Primary AML samples were collected after 
informed consent with approval of the Colorado Multiple Institutional Review Board. Ficoll-
separated mononuclear cells were cultured in IMDM supplemented with 20% BIT Serum 
Substitute, LDL, B-ME, penicillin/streptomycin, L-glutamine, IL-3, FLT-3 ligand, and SCF. 
To assess colony-forming ability, primary samples were plated in Methocult H4434 Classic 
(Stemcell Technologies, Vancouver, BC, Canada). Colonies were counted after 10-14 days 
of continuous drug exposure. AZD1775-resistant cells were generated by culturing Molm13, 
Jurkat, and REH cells in 50-1000 nM AZD1775 over 3 months. 
Lentivirus Preparation 
 CDK1/2-AF constructs were generously provided by Dr. David O. Morgan and 
cloned into response vectors of the Lenti-X Tet-On 3G Inducible System (Clontech 
Laboratories, Inc.) Virus-containing media was prepared according to manufacturer’s 
protocol. OCI-AML3 cells expressing DDp53 and 32D cells expressing FLT3-ITD were 
generated by transduction of target cells with Murine Stem Cell Virus expressing genes of 
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interest followed by an internal ribosome entry site and green fluorescent protein (MSCV-
ires-GFP), as previously described (Van Linden et al., 2013). 
Chemotherapies, Antibodies, and Reagents 
 AZD1775 and olaparib were provided by AstraZeneca (Wilmington, DE). The 
chemical structure of AZD1775 has previously been described (Hirai et al., 2009). 
Cytarabine, vincristine, doxycycline, and puromycin were purchased from Sigma-Aldrich 
(St. Louis, MO) and diluted in water. RO-3306 and roscovitine were purchased from EMD 
Millipore (Billerica, MA) and diluted in DMSO. Vorinostat, panobinostat, and CPI-455 were 
purchased from Selleckchem (Houston, TX). JQ1 was a kind gift from the Bradner 
laboratory. Antibodies specific to actin, PARP, γH2AX, pCDK1 Tyr15, CDK1, pCHK1 
Ser345, c-MYC, tubulin, caspase 3, HA-tag, GAPDH and histone H3 were purchased from 
Cell Signaling Technology (Danvers, MA). The antibody against KDM5A was purchased 
from Bethyl Laboratories (Montgomery, TX), and the antibody against trimethylated histone 
3 lysine 4 was purchased from Active Motif (Carlsbad, CA).  
Comet Assays  
Formation of DNA double strand breaks was assessed using CometAssay kits 
(Trevigen, Gaithersburg, MD). Cells were collected after 72 hours of drug treatment and 
embedded in agarose on slides. Slides were subjected to electrophoresis in TAE buffer 
followed by staining with SYBR Green (Trevigen) and visualization by fluorescent 
microscopy at 4x magnification. CometScore software (TriTek, Summerduck, VA) was used 
to calculate the olive moment, the product of the mean tail migration distance and the 




Cells were treated with AZD1775 and/or olaparib for 48 hours in poly-D-lysine 
coated chamber slides (Sigma-Aldrich, St Louis, MO). Cells were then fixed with 4% 
paraformaldehyde for 15 minutes at room temperature and permeabilized with 0.2% Triton X 
in PBS for 10 minutes. Cells were incubated in blocking solution (5% milk in 0.05% Triton 
X-PBS) for 30 minutes followed by an overnight incubation in anti-Rad51antibody (Cell 
Signaling Technology) at a dilution of 1:500. After several washes, Alexa Fluor 488 
conjugated anti-rabbit antibody (1:500) was applied for 1 hour. ProLong Gold Antifade 
Mountant with DAPI (Life Technologies, Waltham, MA) was used for mounting. Images 
were acquired using an inverted epifluorescence microscope at 100X magnification. 
Flow Cytometry 
Cell viability was determined with the Guava EasyCytePlus (Millipore, Billerica, 
MA) by measuring cell counts with propdium iodide exclusion. Apoptosis was assessed 
using Guava Nexin reagent according to the manufacturer’s protocol (Millipore). Cell cycle 
analysis was performed using Guava Cell Cycle Reagent according the manufacturer’s 
protocol (Millipore). 
Beta-Galactosidase Staining 
Cells were treated with AZD1775 and/or olaparib for 48 hours. After drug treatment, 
cells were placed in drug-free media and cultured in poly-D-lysine coated chamber slides 
(Sigma-Aldrich) for an additional 96 hours. Beta-galactosidase staining was performed using 
the senescence β-galactosidase staining kit according to the manufacturer’s protocol (Cell 




Female 6-week old C57BL/6J mice were purchased from The Jackson Laboratory 
and housed in sterile micro-isolators in the Center for Comparative Medicine at the 
University of Colorado Anschutz Medical Campus (Aurora, CO). Five mice per treatment 
group were used for each of the two experiments for a total of ten mice per treatment group. 
Five hundred thousand luciferase tagged AML cells were injected by tail vein injection into 
un-irradiated recipients to induce leukemia (Pardee et al., 2011). Beginning 3 days later, mice 
were treated 5 days/week with olaparib 50 mg/kg and/or AZD1775 80 mg/kg once per day 
by oral gavage.  Luciferase activity was measured 5 minutes after injection of luciferin using 
a Xenogen IVIS2000 imaging system. Animal studies were approved by the Institutional 
Animal Care and Use Committee of the University of Colorado Denver. 
RNAseq 
 AZD1775-sensitive and -resistant Jurkat cells were treated with panobinostat (10 nM) 
and/or AZD1775 (1 uM) for 24 hr. Total RNA was extracted using a RNeasy kit (Qiagen 
Inc., Valencia, CA). cDNA libraries were constructed for each sample using the TruSeq 
Stranded RNA kit (Illumina Inc, San Diego, CA) according to the manufacturer’s protocol. 
The unique cDNA libraries were sequenced as single-pass 50bp reads on the Illumina 
HiSeq4000 platform at the University of Colorado Genomics and Sequencing Core Facility. 
The resulting sequences were analyzed using a custom pipeline consisting of gSNAP, 
Cufflinks, and R for sequence alignment and identification of differential gene expression as 
previously described (Baird et al., 2014; Wu and Nacu, 2010). Genes with a false discovery 
rate (FDR) < 0.05 were analyzed using Ingenuity Pathways Analysis (Qiagen, Germantown, 
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MD) to identify pathways modified in sensitive and resistant cells treated with AZD1775 
and/or panobinostat.  
Statistical Analysis 
Data analysis and graphing was performed using Graphpad Prism 5 (GraphPad 
Software, La Jolla, CA). Unless otherwise indicated, graphs represent the mean from a 
minimum of three biological replicate experiments, and error bars portray the standard error 
of the mean. One-way ANOVA was used to compare 3 or more samples with a single 
variable. Two-way ANOVA was used to compare 3 or more samples with 2 variables. The 
Bonferroni correction was applied to determine significance between any two conditions. 
Non-linear regression was used to generate dose-response curves and determine IC50 values. 
Combination Index (CI) values were calculated using the equation of Chou and Talay with 
CalcuSyn (Biosoft, Cambridge, United Kingdom) (Chou and Talalay, 1984). CI values were 
classified as CI >1.1, antagonism; CI = 0.9-1.1, additive; CI = 0.85-0.9, slight synergism; CI 
= 0.7-0.85, moderate synergism; CI = 0.3-0.7, synergism; CI = 0.1-0.3, strong synergism; 
and CI < 0.1, very strong synergism (Bhatla et al., 2012). The Mantel-Cox (log-rank) test was 









INCREASED ACTIVITY OF WEE1 TARGETS CDK1 AND CDK2 IS NECESSARY 
FOR THE COMBINATORIAL ACTIVITY OF AZD1775 AND CYTARABINE 
Introduction 
 Advances such as risk-directed chemotherapy have substantially improved survival in 
AML and ALL (Grimwade and Hills, 2009). However, novel therapies are needed for 
patients who relapse or cannot tolerate standard induction treatment. One strategy to improve 
outcomes is addition of targeted agents that enhance the efficacy of chemotherapies currently 
used to treat these diseases. Ara-C is used for both induction and consolidation therapy in 
AML as well as in CNS-directed treatment in ALL (Jabbour et al., 2010; Kouchkovsky I and 
Abdul-Hay, 2016). Ara-C is an analog of deoxycytidine that is incorporated into DNA 
strands during replication resulting in termination of strand elongation (Shahabadi et al., 
2016). The Porter lab has demonstrated that AZD1775 enhances the anti-proliferative effects 
of Ara-C in AML and T-ALL cells by abrogating the S-phase arrest induced by Ara-C and 
increasing DNA damage (Ford et al., 2015; Porter et al., 2012). A complete understanding 
the mechanism of the combinatorial activity of AZD1775 and Ara-C will be necessary to 
identify patients most likely to benefit from treatment as this combination progresses to 
clinical trials. While a number of studies have examined alterations in the cell cycle in 
response to AZD1775 and anti-metabolite chemotherapies such as Ara-C, the relative 
contribution of WEE1 targets CDK1 and CDK2 has not been studied. Thus, I sought to 
understand the contribution of CDK1 and CDK2 to the combinatorial activity of AZD1775 
and Ara-C. I hypothesized that increased activity of CDK1 and/or CDK2 is required for the 
combinatorial activity of AZD1775 and Ara-C. Using genetic models of “WEE1 resistant” 
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CDK1 and CDK2, I demonstrate that increased activity of both CDK1 and CDK2 is required 
to enhance the anti-proliferative effects of Ara-C in a T-ALL cell line. This is confirmed by 
pharmacologic data demonstrating inhibition of CDK1 alone or CDK1 and CDK2 together 
can abrogate the combinatorial effect of AZD1775 and Ara-C. Together, these data highlight 
the unique ability of WEE1 to regulate two CDKs that function in different phases of the cell 
cycle. 
Results 
Expression of WEE1-Resistant CDK1 and CDK2 Enhances the Anti-Proliferative Effects of 
Cytarabine 
 Inhibition of WEE1 reduces inhibitory phosphorylation of CDK1 and/or CDK2 in 
response to DNA damage. This prevents cell cycle arrest at the intra-S or G2/M checkpoint 
and results in an increase in apoptosis (Hirai et al., 2009; Porter et al., 2012). However, it is 
not known whether increased activity of one or both CDKs is required to enhance the 
efficacy of DNA damaging agents. I sought to determine the necessity of CDK1/2 activity in 
the context of Ara-C treatment by expressing ‘WEE1-resistant’ CDK constructs in the T-
ALL cell line Jurkat. These mutant CDK constructs substitute alanine for threonine at 
position 14 and phenylalanine for tyrosine at position 15 yielding CDK constructs that cannot 
be inhibited by phosphorylation (CDK1/2-AF). Previous reports have confirmed expression 
of these constructs results in increased CDK activity (Jin et al., 1996). CDK1/2-AF 
constructs were cloned into doxycycline-inducible vectors, and expression of the HA-tagged 
proteins is observed upon doxycycline treatment (Figure 3.1a). To test the effects of 
CDK1/2-AF expression on cell viability in cytarabine-treated cells, Jurkat cells transduced 
with vector control, CDK1-AF, and/or CDK2-AF plasmids were treated with Ara-C with and 
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without doxycycline. Expression of CDK1-AF or CDK2-AF alone did not sensitize cells to 
cytarabine, but I observe significant sensitization when both CDK1-AF and CDK2-AF are 
expressed (Figure 3.1b). Next, these cell lines were treated with Ara-C in concentrations 
ranging from 0.5 nM to 40 nM. Doxycycline-induced expression of CDK1-AF or CDK2-AF 
alone does not shift the dose-response curve of Ara-C. However, a shift of the dose-response 
curve was observed in cells expressing both CDK1-AF and CDK2-AF. The IC50 was 6.09 
nM when expression of the CDK constructs was not induced, and this decreased to 2.86 nM 
when both constructs were expressed (Figure 3.1c). Thus, increased activity of both CDK1 
and CDK2 enhances the anti-proliferative effects of Ara-C.  
Expression of WEE1-Resistant CDK1 and CDK2 Increases DNA Damage and Apoptosis in 
Cytarabine-Treated Cells 
 The Porter lab and others have demonstrated that AZD1775 enhances DNA damage 
induction and apoptosis in cells treated with Ara-C (Ford et al., 2015; Porter et al., 2012; 
Tibes et al., 2012). Therefore, I questioned whether increased activity of CDK1 and CDK2 
was responsible for these events. Jurkat cells expressing CDK1-AF and/or CDK2-AF were 
treated with Ara-C and/or doxycycline as well as Ara-C and AZD1775 as a positive control. 
Expression of CDK1-AF or CDK2-AF alone did not increase apoptosis as evidenced by a 
lack of cleaved PARP. However, expression of both constructs produced cleaved PARP 
comparable to levels observed in cells treated with Ara-C and AZD1775 (Figure 3.2). I 
observed a slight increase in γH2AX in cells expressing either CDK1-AF or CDK2-AF 
suggesting that increased activity either CDK can induce some DNA damage in cells 
exposed to Ara-C. However, more DNA damage occurs when activity of both CDK1 and  
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Figure 3.1. Expression of CDK1-AF and CDK2-AF sensitizes T-ALL cells to cytarabine.
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Figure 3.1. Expression of CDK1-AF and CDK2-AF sensitizes T-ALL cells to cytarabine. 
A. Jurkat cells transduced with empty vector (pLVX), CDK1-AF, or CDK2-AF constructs
were given no treatment (NT) or doxycycline (1 ug/mL) for 48 hr after which protein lysates
were subjected to western blotting with antibodies specific to HA-tag and GAPDH. B. Jurkat
cells transduced with empty vector (pLVX), CDK1-AF, and/or CDK2-AF were treated with
Ara-C (10 nM) and/or doxycycline (1 ug/mL) for 72 hr. Viable cell counts are normalized to
cells receiving no treatment (NT). Results are shown as mean ± SEM from three independent
experiments. *, P < 0.05. **, P < 0.01. ***, P < 0.001. C. Jurkat cells transduced with empty
vector (pLVX), CDK1-AF, and/or CDK2-AF were treated with doxycycline (1 ug/mL) and
Ara-C (0.5-40 nM) for 72 hr. Viable cell counts are normalized to cells receiving no Ara-C
treatment (NT). Results are shown as mean ± SEM from three independent experiments.
IC50 values for each cell line with and without doxycycline are displayed below the
corresponding graph.
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CDK2 is increased. Surprisingly, expression of both CDK constructs induces less DNA 
damage than AZD1775 in cytarabine-treated cells (Figure 3.2). Thus, increased activity of 
both CDK1 and CDK2 increases DNA damage and apoptosis, but to a lesser extent than 
treatment with AZD1775. 
Inhibition of CDK1 and CDK2 Abrogates the Combinatorial Activity of AZD1775 and 
Cytarabine 
I then asked whether inhibition of CDK1 alone or both CDK1 and CDK2 could 
abrogate the combinatorial activity of AZD1775 and Ara-C. RO-3306 is an ATP-competitive 
inhibitor of CDK1. The drug is 10-fold more selective for CDK1 than for CDK2 and 50-fold 
more selective for CDK1 than for CDK4 and CDK6. (Vassilev et al., 2006). AZD1775 
treatment significantly enhanced the anti-proliferative effects of Ara-C in Jurkat cells, but 
this was reduced when cells were treated with RO-3306 (Figure 3.3a). Next, cells were 
treated with roscovitine, an ATP-competitive inhibitor of CDK1, CDK2, CDK5, and CDK7 
(Cicenas et al., 2015). Inhibition of CDK1 and CDK2 with roscovitine reduced the 
combinatorial effect of AZD1775 and Ara-C in Jurkat cells as well as in the AML cell line, 
MV;411 (Figure 3.3b,c). Roscovitine treatment also reduced apoptosis as evidenced by 
reduced cleaved PARP in cells treated with AZD1775 and Ara-C (Figure 3.3d). Together, 
these data confirm increased activity of CDK1 and CDK2 is required for the combinatorial 
activity of AZD1775 and Ara-C.  
Summary of Findings 
Inhibition of WEE1 sensitizes cancer cells to many DNA damaging agents; however, 
the mechanisms of sensitization are not fully understood. Our group previously reported that  
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Figure 3.2. Expression of CDK1-AF and CDK2-AF increases DNA damage and 
apoptosis in cytarabine-treated cells. Jurkat cells transduced with empty vector (pLVX), 
CDK1-AF, and/or CDK2-AF constructs were treated with the indicated doses of Ara-C, 
doxycycline, and/or AZD1775 for 24 hr. Protein lysates were subjected to western blotting 
with antibodies specific to PARP, γH2AX, and tubulin. 
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Figure 3.3. Inhibition of CDK1 alone or CDK1 and CDK2 reduces the combinatorial effect of AZD1775 and cytarabine. A. 
Relative numbers of viable Jurkat cells treated with DMSO (vehicle control), AZD1775 (200 nM), RO-3306 (2.5 uM), and/or Ara-C 
(10 nM) for 72 hr. Viable cell counts are normalized to cells receiving no treatment (NT). Results are shown as mean ± SEM from 
three independent experiments. **, P < 0.01. B and C. Relative numbers of viable Jurkat (B) or MV4;11 (C) cells treated with DMSO 
(vehicle control), AZD1775 (200 nM), roscovitine (10 uM), and/or Ara-C (10 nM) for 72 hr. Viable cell counts are normalized to cells 
receiving no treatment (NT). Results are shown as mean ± SEM from three independent experiments. *, P < 0.05. **, P < 0.01. ***, P 
< 0.001. D. Jurkat cells were treated with the indicated doses of roscovitine, AZD1775, and/or Ara-C for 24 hr after which protein 
lysates were subjected to western blotting with antibodies specific to PARP and actin.
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AZD1775 sensitized AML and T-ALL cells to Ara-C by abrogating S-phase arrest and 
promoting apoptosis over DNA damage repair (Ford et al., 2015; Porter et al., 2012). This 
work, combined with data from others, provided justification for a proposed clinical trial 
examining the effects of AZD1775 in combination with Ara-C in patients with AML 
(NCT02666950). An enhanced understanding of the mechanism of combinatorial activity 
between AZD1775 and Ara-C will assist in identifying patients most likely to benefit from 
this combination and in anticipating mechanisms of resistance.  
Inhibition of WEE1 reduces inhibitory phosphorylation of CDK1 and CDK2 which 
leads to increased activity of these proteins. Thus, one approach to understanding the 
mechanism of combinatorial activity of AZD1775 and Ara-C is to determine the relative 
contribution of CDK1 and CDK2 activity. Expression of “WEE1 resistant” CDK1 and 
CDK2, but neither alone, was sufficient to enhance the anti-proliferative effects of Ara-C in a 
T-ALL cell line. Expression of CDK1-AF and CDK2-AF also increased apoptosis and DNA
damage in cells treated with Ara-C, but the increase in DNA damage was less than that 
observed in cells treated with AZD1775 and Ara-C. Furthermore, pharmacologic inhibition 
of CDK1 alone or CDK1 and CDK2 reduced the anti-proliferative effects and apoptosis 
induction that occurred in cells treated with AZD1775 and Ara-C. While additional work is 
required to determine how CDK1 and CDK2 cooperate to sensitize cells to Ara-C, this report 




A SMALL-MOLECULE INHIBITOR OF WEE1, AZD1775, SYNERGIZES WITH 
OLAPARIB BY IMPAIRING HOMOLOGOUS RECOMBINATION AND 
ENHANCING DNA DAMAGE AND APOPTOSIS IN ACUTE LEUKEMIA1
Introduction 
Acute leukemia is the most common form of pediatric cancer and a leading cause of 
cancer related deaths in children. While survival rates in children have improved, in part due 
to dose escalation and optimization of chemotherapy regimens, up to 50% of patients with 
AML and 20% of patients with ALL relapse, and the prognosis for these patients is poor 
(Fernandez et al., 2009; Pui et al., 2011).  Outcomes for adult patients with acute leukemia 
are generally worse, particularly in AML where incidence increases with advanced age 
(Lowenberg and Rowe, 2016). Due to its high toxicity, the use of chemotherapy is limited in 
patients over age 60, leaving few treatment options for many AML cases (Esposito et al., 
2015). Further dose escalation in pediatric patients or addition of non-targeted genotoxic 
agents is likely to increase toxicity while imparting minimal improvements in survival to 
these patients, necessitating the advent of novel therapeutic strategies (Burnett et al., 2010). 
One therapeutic strategy that has shown promise in BRCA1/2-mutated solid tumors is 
inhibition of poly (ADP-ribose) polymerase (PARP) (Bryant et al., 2005; Kim et al., 2015). 
The PARP family includes 18 members, 3 of which are enzymes known to function in  
____________________________________ 
Portions of this chapter were reused with permission from Garcia et al., 2017. 
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various DNA-repair processes including the recognition of single strand breaks (SSBs) in 
base excision repair (BER) (De Lorenzo et al., 2013). Impaired BER in PARP-inhibited cells 
results in accumulation of single-strand breaks that are converted to double-strand breaks 
upon collision with replication forks during S phase of the cell cycle (Bryant et al., 2005). 
PARP-inhibited cells rely on homologous recombination (HR) for DNA damage repair and 
survival, and cells possessing defects in the HR pathway are particularly susceptible to PARP 
inhibitors (Ashworth, 2008; Esposito et al., 2015; Mateo et al., 2015; Mo et al., 2016).  
Despite its promise in some solid tumors, the clinical application of PARP inhibitors 
in acute leukemia has been limited. This limited success is partly because mutations in DNA 
damage response (DDR)-associated genes are not common in acute leukemia, which is often 
driven by transcription factor mutations or gene fusions (Esposito and So, 2014; Esposito et 
al., 2015; Wang et al., 2015). However, pharmacologic impairment of the HR pathway could 
potentially sensitize acute leukemia cells to PARP inhibition. One approach to impairing the 
HR pathway is through inhibition of WEE1. In addition to abrogating cell cycle arrest, 
inhibition of WEE1 impairs HR-mediated repair through forced activation of CDK1 and 
subsequent inhibitory phosphorylation of BRCA2 (Krajewska et al., 2013). Therefore, I 
hypothesized that inhibition of WEE1 via AZD1775 would sensitize acute leukemia cells to 
the PARP inhibitor olaparib. My data confirm that inhibition of WEE1 impairs HR in 
olaparib-treated cells. Combined inhibition of WEE1 and PARP1/2 results in a synergistic 
reduction in cellular proliferation in AML and ALL cell lines, likely through impaired HR 
and subsequent DNA damage accumulation and induction of apoptosis. This combination 
extended survival of mice with an MLL-rearranged murine AML. Finally, addition of 
AZD1775 to olaparib treated AML patient samples enhanced DNA damage and apoptosis 
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and reduced colony formation in methylcellulose. In aggregate, these studies indicate that 
combined treatment with olaparib and AZD1775 could be an effective treatment for acute 
leukemia. 
Results 
AZD1775 Impairs Homologous Recombination 
Cells treated with PARP inhibitors require an intact HR pathway to prevent DNA 
damage accumulation. Inhibition of WEE1 impairs HR by promoting increased CDK1 
activity and subsequent inhibitory phosphorylation of BRCA2 (Krajewska et al., 2013). 
Thus, I sought to determine if inhibition of WEE1 could reduce HR in acute leukemia cells 
treated with the PARP1/2 inhibitor olaparib. To assess this, I selected five cell lines 
representing 3 subtypes of acute leukemia. MV4;11 and Molm13 are AML cells lines that 
possess MLL rearrangements and FLT3 internal tandem duplications, while OCI-AML3 cells 
harbor mutations in NPM1 and DNMT3A. Jurkat is a T-cell ALL line with a mutated TP53 
gene, and REH is a B-cell ALL cell line that harbors an ETV6-RUNX1 fusion. 
First, I examined the anti-proliferative effect of olaparib and AZD1775 as single 
agents in short-term liquid culture. Both olaparib and AZD1775 had similar single agent 
activity in MV4;11, Molm13, Jurkat, and REH cells (Figure 4.1). In light of the inhibitory 
effect of olaparib on these cell lines in this short-term assay, I next addressed whether they 
were competent in homologous recombination. Query of the Cancer Cell Line Encyclopedia 
revealed heterozygous mutations in homologous recombination pathway genes, BRCA 
(Molm13 and REH) and NBN (MV4;11), although the extent to which these mutations impair 
homologous recombination is unknown. Thus, I sought to determine whether these cell lines  
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Figure 4.1. Single agent treatment with olaparib or AZD1775 reduces cell viability and 
enhances apoptosis in AML and ALL cell lines. A. MV4;11, Molm13, Jurkat, and REH 
cells were treated with 0.25 uM- 20 uM olaparib for 72 hr. Percent of viable cells relative to 
cells receiving no treatment (NT) are shown. The IC50 value of each cell line is displayed. B. 
MV4;11, Molm13, Jurkat, and REH cells were treated with 0.25 uM- 20 uM olaparib for 72 
hr and stained with Annexin V-PE. The EC50 value of each cell line is displayed. C. 
MV4;11, Molm13, Jurkat, and REH cells were treated with 25 nM – 2000 nM AZD1775 for 
72 hr. Percent of viable cells relative to cells receiving no treatment (NT) are shown. The 
IC50 value of each cell line is displayed. D. MV4;11, Molm13, Jurkat, and REH cells were 
treated with 25 nM – 2000 nM AZD1775 for 72 hr and stained with Annexin V-PE. The 
EC50 value of each cell line is displayed. 
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had intact HR in a functional assay. PARP1 deficiency or inhibition enhances the 
accumulation of Rad51 foci in cells in which the HR machinery is functional (Schultz et al., 
2003). In response to olaparib treatment, each cell line displayed a significant increase in 
Rad51 foci formation indicating these cell lines are capable of activating the HR pathway 
(Figure 4.2). After demonstrating an increase in Rad51 foci in response to olaparib treatment, 
I sought to determine whether addition of AZD1775 could impair activation of the HR 
pathway. Indeed, when MV4;11 cells were treated with AZD1775 and olaparib, I observed 
reduced Rad51 foci compared to cells treated with olaparib alone (Figure 4.3a,b). Thus, 
inhibition of WEE1 impairs HR in olaparib-treated leukemia cells, consistent with previous 
findings in breast cancer cells (Krajewska et al., 2013).  
AZD1775 Synergizes with Olaparib in Acute Leukemia Cell Lines and Reduces Proliferative 
Capacity Upon Drug Withdrawal 
As AZD1775 impaired HR in cells treated with olaparib, I sought to determine 
whether cells treated with AZD1775 and olaparib demonstrate reduced viability compared to 
cells treated with olaparib alone. At doses achievable in the plasma of patients (Leijen et al., 
2016), AZD1775 potentiated the reduction in proliferation induced by olaparib in four out of 
five cell lines (Figure 4.4a and 4.5a). In order to better model a clinical setting in which 
cancer cells are exposed to varying drug concentrations over time, I examined a wider range 
of drug combinations in MV4;11 cells. Using Chou and Talay median effects analysis, I 
determined that 18 out of the 20 combinations analyzed were synergistic (CI < 1.0), with 
higher concentrations of olaparib and AZD1775 resulting in greater levels of synergy (Table 
4.1). Treatment with 6 dose combinations of olaparib and AZD1775 yielded CI values that 
were additive to moderately synergistic in Molm13 and REH cells (CI: 0.931-0.627 and  
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Figure 4.2. AML and ALL cell lines display elevated homologous recombination in 
response to olaparib treatment. A-E. MV;411 (A), Molm13 (B), Jurkat (C), REH (D), and 
OCI-AML3 (E) cells received no treatment (NT) or were treated with olaparib (2 uM) for 72 
hr then fixed and stained with anti-Rad51 (primary antibody), Alexa Fluor 488 conjugated 
secondary antibody, and DAPI. Representative images are shown. Rad51 foci per cell were 
quantified and are displayed to the right of the images. Results are shown and mean ± SEM 
calculated from a minimum of 50 cells per condition. ***, P < 0.001. ****, P < 0.0001. 
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Figure 4.3. AZD1775 inhibits homologous recombination in olaparib-treated cells. A. 
MV;411 cells were treated with DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 
(200 nM) for 48 hr after which cells were fixed and stained with anti-Rad51 (primary 
antibody), Alexa Fluor 488 conjugated secondary antibody, and DAPI. Representative 
images are shown. B. Rad51 foci per cell was calculated from a minimum of 10 
immunofluorescent images. Results are displayed as mean ± SEM from a minimum of 100 
cells per condition. ****, P < 0.0001. 
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Figure 4.4. AZD1775 enhances the anti-proliferative effects of olaparib in leukemia 
cells. A. Relative numbers of viable cells treated with DMSO (vehicle control), olaparib (2 
uM), and/or AZD1775 (200 nM) for 72 hr. Viable cell counts are normalized to cells 
receiving no treatment (NT). Results are shown as mean ± SEM from three independent 
experiments. *, P < 0.05. **, P < 0.01. ***, P < 0.001, ****, P < 0.0001. B. Live cell number 
of NT AML and ALL cell lines or treated with the indicated concentrations of DMSO 
(vehicle control), olaparib, and/or AZD1775 for 72 hr, removed from drug and cultured in 
fresh media for another 72 hr. Results are displayed as mean ± SEM from three independent 
experiments. Displayed P values were calculated by two-way ANOVA. 
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Figure 4.5. Inhibition of endogenous P53 in OCI-AML3 cells does not enhance the 
combinatorial activity of AZD1775 and olaparib. A-C. OCI-AML3 parental (A), MiG (B), 
and MiG-DDp53 (C) cells were treated with DMSO (vehicle control), olaparib (2 uM), 
and/or AZD1775 (200 nM) for 72 hr. Viable cell counts are normalized to cells receiving no 
treatment (NT). Results are shown as mean ± SEM from three independent experiments. *, P 
< 0.05. **, P < 0.01. ***, P < 0.001. 
Table 4.1. Combination index values for MV4;11 cells treated with olaparib and 
AZD1775 for 72 hours. 
AZD1775 (nM) 
Olaparib (uM) 50 100 200 400 800 
0.25 0.787 0.963 0.914 0.641 0.804 
0.5 0.867 0.881 0.994 0.891 0.597 
1.0 0.976 1.138 0.814 0.546 0.678 
2.0 1.028 0.943 0.547 0.420 0.588 
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CI: 0.983-0.654, respectively) and additive to slightly synergistic in Jurkat cells (CI: 1.025-
0.805; not shown). CI values from OCI-AML3 cells were antagonistic to additive (CI: 1.817-
0.994). 
Previous reports by others have suggested that cells lacking functional P53 are reliant 
on WEE1 to maintain genomic integrity when exposed to DNA damaging agents (Marusyk 
et al., 2007). Since OCI-AML3 cells (with functional P53) had the least response to the 
combination of AZD1775 and olaparib, I used these cells to test whether impaired P53 
function sensitizes these cells to combination therapy. I inhibited P53 in OCI-AML3 cells, by 
stably expressing the dominant negative dimerization domain of P53 (DDp53) from MSCV-
ires-GFP as the Porter lab has done before (Van Linden et al., 2013). AZD1775 did not 
sensitize OCI-AML3-ddP53 cells to olaparib (Figure 4.5), indicating that the sensitivity to 
AZD1775 and olaparib is independent of P53 functionality and consistent with my data from 
cell lines with (Jurkat) and without (MV4;11, Molm13, REH) TP53 mutation. As sensitive 
AML cell lines (Molm13, MV4;11) harbor FLT3-ITD, while the insensitive OCI-AML3 cell 
lines do not, and FLT3-ITD is associated with impaired DNA damage response (Fan et al., 
2010; Sallmyr et al., 2008), our lab expressed FLT3-ITD, in the 32D murine myeloid 
progenitor cell line, but did not observe enhanced reduction in proliferation in cells 
expressing these oncogenes (Figure 4.6), suggesting that FLT3-ITD is not a marker predictive 
of sensitivity to AZD1775 and olaparib. 
As cancer cells often recover proliferative capacity after treatment with 
chemotherapeutics, I sought to determine if AZD1775 could prevent proliferation in 
olaparib-treated cells once drug was removed. To accomplish this, cells were treated with 
olaparib and/or AZD1775 for 72 hours then re-plated without drug and cultured for an  
66 
Figure 4.6. FLT3-ITD does not enhance the combinatorial activity of AZD1775 and 
olaparib. The 32D cell line was transduced with FLT3-ITD or empty vector and treated with 
olaparib at the indicated doses and/or AZD1775 (100nM) in triplicate for 72 hours. 
Proliferation and viability were assessed by Cell Titer Glow, per the manufacturer’s 
instructions, and normalized to the value of untreated (UT) cells. Results are displayed as 
mean ± SEM from 3 independent experiments. 
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additional 72 hours. While olaparib treatment resulted in decreased proliferative capacity, 
addition of AZD1775 prevented the recovery of cells compared to single agent treatment 
(Figure 4.4b). Collectively, these results reveal the potential therapeutic utility of olaparib 
and AZD1775 in a variety of, but not all, acute leukemia subtypes. 
AZD1775 Enhances DNA Damage, Apoptosis, and Senescence Induced by Olaparib 
As cells with impaired PARP activity require HR to resolve single strand breaks that 
occur spontaneously, I hypothesized that impaired HR induced by WEE1 inhibition would 
result in accumulation of DNA damage in cells treated with olaparib and AZD1775 (Bryant 
et al., 2005). To test this hypothesis, I used the alkaline comet assay to visualize double 
strand breaks (DSBs) in cells treated with olaparib and/or AZD1775. AZD1775 enhanced 
DNA damage in olaparib-treated cells as evidenced by the prevalence of distinct comet tails 
(Figure 4.7a). Indeed, the addition of AZD1775 enhanced the average olive moment by 
approximately 10-fold compared to olaparib alone (Figure 4.7b). This increase in DNA 
damage was confirmed by increased γH2AX in cells with both PARP and WEE1 inhibition 
(Figure 4.7c). 
To determine whether addition of AZD1775 to olaparib induced more apoptosis 
compared to olaparib alone, I measured apoptosis by Annexin V staining after 72 hours of 
treatment.  The addition of AZD1775 to olaparib lead to significantly more apoptosis than 
with either agent alone (Figure 4.7d). I also observed an increase in cleaved caspase 3 
accompanied by reduced pro caspase 3 in MV4;11 cells treated with olaparib and AZD1775, 
further suggesting increased apoptosis in cells treated with both PARP and WEE1 inhibitors 
(Figure 4.7e).  
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Figure 4.7. Combined AZD1775 and olaparib treatment enhances DNA damage 
accumulation, apoptosis induction, and senescence. 
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Figure 4.7. Combined AZD1775 and olaparib treatment enhances DNA damage 
accumulation, apoptosis induction, and senescence. A. MV4;11 cells were treated with 
DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 (200 nM) for 72 hr and analyzed 
via Comet assay. Images are representative from one of three independent experiments. B. 
Olive moment values normalized to MV4;11 cells receiving no treatment (NT). Results are 
shown as mean ± SEM from one of three independent experiments. A minimum of 50 cells 
per experiment were analyzed. ****, P < 0.0001. C. MV4;11 cells were treated with DMSO 
(vehicle control), olaparib (2 uM) and/or AZD1775 (200 nM) for 48 hr after which protein 
lysates were subjected to western blotting using antibodies specific to γH2AX and tubulin. D. 
Indicated cell lines were treated with DMSO (vehicle control), olaparib (2 uM), and/or 
AZD1775 (200 nM) for 72 hr and stained with Annexin V-PE. Results are displayed as mean 
± SEM of three independent experiments. *, P < 0.05. **, P < 0.01. ***, P < 0.001. ****, P < 
0.0001. E. MV4;11 cells were treated with DMSO (vehicle control), olaparib (2 uM), and/or 
AZD1775 (200 nM) for 48 hr after which protein lysates were subjected to western blotting 
using antibodies specific to caspase 3 and tubulin. F and G. Molm13 (F) and REH (G) cells 
were treated with DMSO (vehicle control), olaparib (1 uM), and/or AZD1775 (100 nM) for 
48 hr, re-plated in drug-free media for an additional 96 hr, then fixed and stained for β-
galactosidase. Images are representative from one of two independent experiments. Percent 
of β-gal positive cells are quantified to the right. A minimum of 200 cells per condition was 
analyzed. ****, P < 0.0001. 
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As cells treated with olaparib and AZD1775 fail to recover proliferative capacity 
upon drug removal (Figure 4.4b), I sought to determine whether the drug combination 
induced senescence in surviving cells. To test this, Molm13 and REH cells were treated with 
AZD1775 and/or olaparib for 48 hours. After drug treatment, cells were re-plated in drug-
free media for an additional 96 hours then fixed and stained for beta-galactosidase. In 
Molm13, I observed a 6-fold increase in beta-galactosidase positive cells in cells treated with 
olaparib and AZD1775 compared to cells treated with olaparib alone (Figure 4.7f). REH cells 
treated with the drug combination displayed an 8-fold increase in beta-galactosidase positive 
cells compared to cells treated with only olaparib (Figure 4.7g). Thus, treatment with 
olaparib and AZD1775 increases senescence compared with cells treated with olaparib alone. 
The Porter lab and others have previously demonstrated that AZD1775 enhances the 
efficacy of some genotoxic agents by abrogating cell cycle arrest at the intra-S or G2/M 
checkpoints that occurs in cells treated with chemotherapy alone (Indovina et al., 2014; 
Porter et al., 2012). Therefore, I examined whether changes in the cell cycle occur in cells 
treated with olaparib and AZD1775. Jurkat cells treated with olaparib display a G2/M phase 
arrest, and this is abrogated with addition of AZD1775 (Figure 4.8a,c). Additionally, 
Molm13 cells treated with the drug combination have a decreased percentage of cells in the 
G2/M phase, although olaparib alone does not induce a G2/M phase arrest in this cell line 
(Figure 4.8a). However, I did not observe similar changes in other cell lines tested indicating 
that altered cell cycle progression is not a unifying mechanism responsible for the 
combinatorial activity of olaparib and AZD1775 (Figure 4.8a,b). Together, these results 
indicate that combined inhibition of WEE1 and PARP1/2 enhances accumulation of DNA 
DSBs, apoptosis, and senescence, independent of cell cycle effects of the drugs. 
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Figure 4.8. Cell cycle analysis of acute leukemia cells treated with AZD1775 and olaparib. A. The indicated cell lines were 
treated with DMSO (vehicle), olaparib (2 uM), and/or AZD1775 (200 nM) for 48 hr then fixed and stained with propidium iodide. 
Results are shown as mean ± SEM from a minimum of two independent experiments. B. MV4;11 cells were treated with DMSO 
(vehicle), olaparib (2 uM), and/or AZD1775 (200 nM) for 48 hr then fixed and stained with propidium iodide. Representative plots are 
displayed.  C. Jurkat cells were treated with DMSO (vehicle), olaparib (2 uM), and/or AZD1775 (200 nM) for 48 hr then fixed and 
stained with propidium iodide. Representative plots are displayed. 
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Combined AZD1775 and Olaparib Treatment Enhances Survival of Mice with Murine AML 
I then asked whether AZD1775 and olaparib treatment could slow leukemia 
progression in vivo. For these studies, I selected a murine MLL-ENL, FLT3-ITD+ AML cell 
line that responds to combined treatment with olaparib and AZD1775 in vitro (Figure 4.9). 
The murine AML cells were injected via tail vein into mice as previously described (Van 
Linden et al., 2013). Single agent treatment with either olaparib or AZD1775 failed to 
enhance survival compared to vehicle controls (olaparib or AZD1775 median survival: 17 
days; vehicle median survival: 14 days) (Figure 4.10c). However, the combination treatment 
slowed leukemia progression as measured by luciferase expression and extended median 
survival to 31 days (Figure 4.10a-c). Mouse weights and complete blood counts were 
assessed 7 days after treatment initiation to evaluate toxicity. Mice receiving combination 
treatment had reduced hemoglobin levels compared to mice treated with vehicle control or 
olaparib; however, there was no change in weight, red blood cell counts, white blood cell 
counts, or platelet levels with either single agent or combination treatment (Figure 4.11). 
Two of the ten mice treated with AZD1775 and olaparib were euthanized due to ill 
appearance, although no evidence of leukemia was observed at the time of sacrifice. 
AZD1775 Enhances Apoptosis Induction and Reduces Colony Formation in AML Patient 
Samples 
I next examined the effects of AZD1775 and olaparib on cell viability, apoptosis 
induction, and colony formation on AML patient samples. Samples with baseline apoptosis 
greater than 40% 72 hours after plating or that did not form colonies under no treatment 
conditions were excluded from analysis (Figure 4.12). Patient sample AML 10-5-10 harbors 
a FLT3-ITD mutation (Lee-Sherick et al., 2015), but genetic information for the other patient 
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Figure 4.9. Combined AZD1775 and olaparib treatment reduces cell viability and 
enhances apoptosis in a murine AML cell line. A. A murine MLL-ENL, FLT3-ITD+ AML 
cell line was treated in vitro with DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 
(200 nM) for 72 hr. Viable cell counts are normalized to cells receiving no treatment (NT). 
Results are shown as mean ± SEM from three independent experiments. *, P < 0.05. **, P < 
0.01. ***, P < 0.001. ****, P < 0.0001. B. A murine AML cell line was treated in vitro with 
DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 (200 nM) for 72 hr then stained 
with Annexin V-PE. Results are displayed as mean ± SEM of three independent experiments. 
**, P < 0.01. ***, P < 0.001. ****, P < 0.0001. 
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Figure 4.10. Combined treatment with AZD1775 and olaparib improves survival in a 
murine AML model. A. Murine AML cells were injected intravenously into C57BL/6J 
mice, and treatment was initiated 3 days after leukemia transfer. Mice were treated 5 days per 
week until leukemia burden as measured by luciferase intensity reached the threshold for 
sacrifice. Displayed images are representative IVIS imaging acquired 10 days after leukemia 
transfer. B. Quantified luciferase activity 10 days after leukemia transfer. Results are 
displayed as mean ± SEM from two independent experiments. **, P < 0.01 (vehicle vs. 
olaparib + AZD1775). C. Kaplan-Meier curve of mice with murine AML treated as 
indicated. Results are shown from 2 independent experiments.  
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Figure 4.11. Combined AZD1775 and olaparib treatment is tolerated in vivo. A and B. 
Mice injected with a murine AML cell line were treated as described in the text. Complete 
blood counts (A) and weights (B) were obtained 10 days after leukemia transfer. Results are 
displayed as mean ± SEM from 2 independent experiments. *, P < 0.05. **, P < 0.01. 
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Figure 4.12. AZD1775 enhances the anti-proliferative effects of olaparib in AML 
patient samples with high baseline apoptosis or limited colony-forming ability. A and B. 
AML patient samples were treated with DMSO (vehicle control), olaparib (2 uM), and/or 
AZD1775 (200 nM) for 72 hr and analyzed for cell viability (A) and apoptosis induction (B). 
Live cell counts are normalized to cells receiving no treatment (NT). Results are shown as 
mean ± SEM of 2 technical replicates. 
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Figure 4.13. AZD1775 and olaparib reduce proliferation and colony formation and 
induce apoptosis in AML patient samples. A and B. AML patient samples were treated 
with DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 (200 nM) for 72 hr and 
analyzed for cell viability (A) and apoptosis induction (B). Results are displayed as mean ± 
SEM of two technical replicates. C. Quantification of colonies formed in methylcellulose 
after continuous exposure to DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 
(200 nM) for 10-14 days. Results are normalized to cells receiving no treatment (NT) and are 
displayed as mean ± SEM of three technical replicates. D. Representative images of AML 
sample 7293 colonies formed after 10 days of continuous exposure to DMSO (vehicle 
control), olaparib (2 uM), and/or AZD1775 (200 nM). E. Patient sample AML 10-5-10 was 
treated with DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 (nM) for 48 hr after 
which protein lysates were subjected to western blotting using antibodies specific to γH2AX 
and actin. 
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samples was not available. Exposure to the drug combination resulted in a reduction in viable 
cell numbers, an increase in apoptotic cells, and a decline in colony formation (Figure 4.13a, 
b, c). Further supporting reduced colony forming ability, the colonies that did form in cells 
exposed continuously to AZD1775 and olaparib were smaller than those in cells exposed to 
olaparib (Figure 4.13d). Similar to my observations in cell lines, combined treatment with 
olaparib and AZD1775 enhanced DNA damage as evidenced by elevated γH2AX (Figure 
4.13e). Thus, combined olaparib and AZD1775 treatment could be an effective therapeutic 
approach for acute leukemia.  
Summary of Findings 
While improvements to chemotherapy regimens have increased survival of patients 
with acute leukemia, outcomes remain poor for patients that relapse and for elderly patients 
that cannot tolerate standard treatment (Carroll and Raetz, 2012; Krug et al., 2011). Thus, 
novel treatment options are necessary to improve outcomes in these patient populations. In 
this study, I have identified the rational combination of AZD1775 and olaparib as a novel 
therapeutic option for the treatment of acute leukemia. AZD1775 inhibited HR in olaparib-
treated cells, resulting in increased DNA damage and apoptosis. Surviving cells treated with 
the combination displayed an increase in senescence and reduced proliferative capacity upon 
drug removal compared with cells treated with either drug alone. The doses of AZD1775 that 
I used in vitro are comparable to the IC50 of this compound in cell based assays in which 
phosphorylation of CDK is inhibited, and lower than achieved in vivo in an early phase 
clinical trial (Do et al., 2015). Similarly, the concentrations of olaparib used in vitro can be 
achieved in vivo (Del Conte, 2014), although they are higher than is necessary to inhibit 
poly-(ADP)-ribosylation in vitro (Menear et al., 2008). In contrast to AZD1775 combined 
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with conventional chemotherapy agents, the synergy between AZD1775 and olaparib seems 
to be independent of the cell cycle effects of these drugs. It should be noted that AZD1775 
sensitized some, but not all, cell lines to olaparib. Future studies are required to identify 
markers predictive of sensitivity to this combination. This will be informative in the design 
of clinical trials to ensure patients most likely to respond are included while those likely to 
experience toxicity with minimal added benefit are not. AZD1775 enhanced disease control 
and prolonged survival in mice with murine AML. This combination also reduced 
proliferation and colony formation and enhanced DNA damage and apoptosis in AML 
patient samples, indicating this could be an effective combination for leukemia control in 
some patients. 
In summary, this report describes a novel synergistic combination, AZD1775 and 
olaparib, for the treatment of acute leukemia. I have demonstrated that pharmacologic 
inhibition of WEE1 has potential to broaden the application of PARP inhibitors beyond the 
current use in BRCA1/2-mutant cancers. Taken together, these data provide support for 
clinical trials testing AZD1775 and olaparib for acute leukemia. 
80 
CHAPTER V 
ACQUIRED RESISTANCE TO AZD1775 IS MEDIATED BY HDAC REGULATED 
EXPRESSION OF C-MYC 
Introduction 
Inhibition of WEE1 is emerging as a promising therapeutic strategy in cancer. Many 
preclinical studies have demonstrated that inhibition of WEE1 enhances the efficacy of DNA 
damaging agents. For example, AZD1775, a small-molecule inhibitor of WEE1, synergizes 
with cytarabine in AML and T-ALL cells (Ford et al., 2015; Porter et al., 2012), with 
cisplatin in medulloblastoma cells (Harris et al., 2014), and with doxorubicin in colon 
adenocarcinoma cells (Hirai et al., 2010). AZD1775 has also been identified as an effective 
monotherapy in cancers including NSCLC, ovarian clear cell carcinoma, and melanoma 
(Guertin et al., 2013). According to ClinicalTrials.gov (accessed May 2017), 37 clinical 
studies are investigating the effectiveness of AZD1775 in monotherapy and in combination 
with DNA damaging agents in both solid tumors and hematologic malignancies. 
Despite promising preclinical results, development of resistance is a major hurdle in 
the clinical application of kinase inhibitors (Barouch-Bentov and Sauer, 2011). Thus, the aim 
of the present study is to identify potential mechanisms of acquired resistance to AZD1775. 
Cancer cells can develop resistance to drugs by a variety of mechanisms including increased 
drug efflux, acquisition of mutations that prevent the binding of drug to target, and activation 
of compensatory survival pathways (Sharma et al., 2010). Beyond these mechanisms, recent 
studies have described a reversible “drug-tolerant” state mediated by altered epigenetic 
regulation of gene expression (Banelli et al., 2015; Pribluda et al., 2015; Sharma et al., 2010). 
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Specifically, increased activity of KDM5A leading to a reduction in histone 3 lysine 4 
trimethylation (H3K4me3) has been shown to mediate resistance to gefitinib and cisplatin in 
NSCLC cells and to temozolomide in glioblastoma cells. Knockdown of KDM5A or 
inhibition of HDACs which bind to and regulate the activity of KDM5A was capable of 
reversing drug resistance in these studies (Banelli et al., 2015; Sharma et al., 2010). 
Consistent with these studies, I found that acquired resistance to AZD1775 in three acute 
leukemia cell lines could be reversed with HDAC or KDM5 inhibition. Furthermore, I 
demonstrate that AZD1775-resistant cells have increased c-MYC expression which is 
reduced upon treatment with HDAC inhibitors. Treatment with JQ1 which has previously 
been reported to inhibit c-MYC expression (Venkataraman et al., 2014) partially reversed 
resistance to AZD1775. Collectively, these studies indicate HDAC-mediated overexpression 
of c-MYC has potential to drive resistance to AZD1775 in acute leukemia cells. 
Results 
Generation and characterization of AZD1775-resistant acute leukemia cell lines 
Despite initial clinical response to kinase inhibitors, development of resistance 
frequently occurs (Lovly and Shaw, 2014). To understand potential mechanisms of resistance 
to AZD1775, our group generated resistance in three acute leukemia cell lines. These cell 
lines represent three major subtypes of acute leukemia and have diverse genetic backgrounds. 
Molm13 is an AML cell line with a MLL rearrangement and FLT3-ITD mutation. Jurkat is a 
T-ALL cell line that possesses a TP53 mutation, and REH is a B-ALL line with an ETV6-
RUNX1 fusion and a MLH1 mutation. Resistance was generated by continuously culturing 
these cell lines in media containing 50-1000 nM AZD1775 over a period of 3 months. Each 
resistant cell line displayed significantly less sensitivity to the anti-proliferative effects of 
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AZD1775 (Figure 5.1a-c). REH resistant cells had a 3.6-fold reduction in sensitivity as 
measured by IC50 values. Molm13 resistant cells had an IC50 value 4.9-fold higher than the 
sensitive cell line, and resistant Jurkat cells had an IC50 7.3-fold higher than matched 
sensitive cells (Figure 5.1a-c). Previous reports have demonstrated that increased drug efflux 
or the development of gatekeeper mutations that prevent a drug from binding to its target can 
drive resistance to small-molecule inhibitors (Barouch-Bentov and Sauer, 2011; Gottesman, 
2002). Thus, I sought to determine whether either of these mechanisms could be contributing 
to resistance to AZD1775. Sanger sequencing of DNA from AZD1775-resistant cells 
identified no mutations in the WEE1 gene (data not shown). Additionally, resistant cells 
treated with AZD1775 at concentrations lower than the IC50 display reduced WEE1 activity 
as evidenced by decreased phosphorylation of CDK1 at tyrosine 15 (Figure 5.1d-f). Thus, 
resistance to AZD1775 is not due to reduced cellular concentrations or activity of the drug in 
all three resistant cell lines. 
Drug resistance due to altered cellular signaling or gene expression in the absence of 
mutations is frequently reversible when resistant cells are released from the selective pressure 
of the drug (Banelli et al., 2015; Sharma et al., 2010). To determine whether resistance to 
AZD1775 is reversible, I cultured each resistant cell line in drug-free media for 40 passages. 
Resistant cells cultured in drug-free media have increased sensitivity to AZD1775 compared 
with resistant cells maintained in AZD1775 (Figure 5.1g-i). While the resistant cells cultured 
in drug-free media are still less sensitive to AZD1775 compared to the sensitive cell lines, 
these data indicate resistance to AZD1775 is at least partially reversible upon drug removal.  
Treatment with AZD1775 results in increased replication origin firing which leads to 
nucleotide shortage, replication fork slowing, and DNA damage induction  
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Figure 5.1. Generation and characterization of AZD1775-resistant cell lines. 
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Figure 5.1. Generation and Characterization of AZD1775-Resistant Cell Lines. A-C. 
AZD1775-sensitive and -resistant Molm13 (A), Jurkat (B), and REH (C) cells were treated 
with 50-2000 nM AZD1775 for 72 hr. Viable cell counts normalized to cells receiving no 
treatment (NT) are shown. Results are shown as mean ± SEM from three independent 
experiments. IC50 values for each cell line are displayed below the corresponding graph. D-
F. Molm13 (D), Jurkat (E), and REH (F) sensitive and resistant cells were treated with the 
indicated concentrations of AZD1775 for 24 hr after which protein lysates were subjected to 
western blotting with antibodies specific to pCDK1 tyrosine 15, CDK1, and actin. G-I. 
Molm13 (G), Jurkat (H), and REH (I) cells resistant to AZD1775 were cultured in drug-free 
media for 40 passages. Sensitive and resistant cells as well as resistant cells cultured in drug-
free media were treated with 50-2000 nM AZD1775 for 72 hr. Viable cell counts normalized 
to cells receiving no treatment are shown. Results are shown as mean ± SEM from three 
independent experiments. 
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(Beck et al., 2012). Thus, prevention of DNA damage induction or elevation of DNA damage 
repair might induce resistance to WEE1 inhibition, and cells capable of avoiding DNA 
damage accumulation could be resistant to additional DNA damaging agents. To assess this, 
sensitive and resistant cells were treated with Ara-C and vincristine, two conventional 
chemotherapy agents used for induction therapy of AML and ALL, respectively. AZD1775-
resistant Molm13 and REH cells were equally sensitive to Ara-C compared with AZD1775-
sensitive cells (Figure 5.2a,c). Resistant Jurkat cells were slightly more sensitive to Ara-C 
than the sensitive cells (Figure 5.2b). Resistance to AZD1775 was not associated with 
reduced sensitivity to vincristine in Jurkat and REH cells, but AZD1775-resistant Molm13 
cells were less sensitive to vincristine (IC50: 0.336 nM (sensitive cells) vs. 0.613 nM 
(resistant cells)) (Figure 5.2d-f). The variable response to conventional chemotherapeutics 
suggests these cell lines may vary in ability to repair DNA damage. However, cells resistant 
to AZD1775 are not broadly resistant to DNA damaging agents.  
While some studies suggest AZD1775 might be effective in single-agent therapy, the 
majority of pre-clinical studies with AZD1775 have been performed in combination with 
DNA damaging agents (Guertin et al., 2013). As AZD1775 will likely be used in 
combination with DNA damaging agents rather than as single-agent therapy for the treatment 
of acute leukemia, I sought to determine whether cells resistant to single-agent AZD1775 
were also resistant to AZD1775 combined with Ara-C. Consistent with previous results from 
the Porter lab (Ford et al., 2015; Porter et al., 2012; Van Linden et al., 2013), AZD1775 
enhanced the anti-proliferative effects of Ara-C in AZD1775-sensitive cell lines. However, 
AZD1775 did not sensitize resistant cells to Ara-C at concentrations effective in sensitive 
cells (Figure 5.3). Therefore, cells resistant to single-agent AZD1775 treatment also display  
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Figure 5.2. AZD1775-resistant cells are not broadly resistant to DNA damaging agents. 
A-C. AZD1775-sensitive and -resistant Molm13 (A), Jurkat (B), and REH (C) cells were
treated with 5-50 nM Ara-C for 72 hr. Viable cell counts normalized to cells receiving no
treatment (NT) are shown. Results are shown as mean ± SEM from three independent
experiments. D-F. AZD1775-sensitive and -resistant Molm13 (D), Jurkat (E), and REH (F)
cells were treated with 0.5-2 nM vincristine for 72 hr. Viable cell counts normalized to cells
receiving no treatment (NT) are shown. Results are shown as mean ± SEM from three
independent experiments.
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Figure 5.3. AZD1775-resistant cell lines are resistant to AZD1775 combined with Ara-
C. A-C. AZD1775-sensitive and -resistant Molm13 (A), Jurkat (B), and REH (C) cells were
treated with AZD1775 (200 nM) and/or Ara-C (20 nM) for 72 hr. Viable cell counts are
normalized to cells receiving no treatment (NT). Results are displayed as mean ± SEM from
a minimum of two independent experiments.
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reduced sensitivity to AZD1775 combined with Ara-C. 
HDAC Inhibition Increases Sensitivity to AZD1775 in Resistant Cell Lines 
The observation that resistance to AZD1775 is partially reversible after prolonged 
treatment in drug-free media lead me to consider epigenetic mechanisms of resistance. As 
HDAC inhibition has been demonstrated to abrogate resistance to a number of drugs 
including imatinib in CML cells and gefitinib and cisplatin in lung cancer cells (Pribluda et 
al., 2015), I asked whether HDAC inhibition could sensitize resistant acute leukemia cells to 
AZD1775. Treatment with pan-HDAC inhibitors panobinostat or vorinostat enhanced the 
anti-proliferative effects of AZD1775 in resistant Molm13, Jurkat, and REH cells (Figure 
5.4). HDAC inhibition reduced the IC50 of AZD1775 in resistant cells to values comparable 
to those in sensitive cells (Table 5.1).  
Next, cells were treated with panobinostat, vorinostat, and/or AZD1775 to determine 
whether HDAC inhibition could restore DNA damage and apoptosis induction in response to 
WEE1 inhibition. Sensitive cells treated with AZD1775 display a dose-dependent increase in 
Annexin V positive cells indicating an increase in apoptosis (Figure 5.5a-c). Although 
resistant Molm13 and REH cells have slightly higher levels of apoptosis at baseline 
compared with sensitive cells, none of the three resistant cell lines have increased apoptosis 
induction upon treatment with AZD1775 (Figure 5.5a-c). HDAC inhibition alone does not 
increase apoptosis in resistant cells; however, it does promote a dose-dependent increase in 
apoptosis in response to AZD1775 as indicated by increased Annexin V positive cells. 
Further supporting an increase in apoptosis, treatment with panobinostat or vorinostat 
resulted in an increase in cleaved PARP in resistant cells treated with AZD1775 (Figure 
5.5d-f). HDAC inhibition also increases DNA damage induction, as evidenced by elevated  
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Figure 5.4. HDAC inhibition enhances the anti-proliferative effects of AZD1775 in 
resistant cells. A-C. AZD1775-sensitive and -resistant Molm13 (A), Jurkat (B), and REH 
(C) cells were treated with the indicated concentrations of panobinostat and/or 25-2000 nM
AZD1775 for 72 hr. Viable cell counts normalized to cells receiving no AZD1775 treatment
(NT) are shown. Results are shown as mean ± SEM from a minimum of three independent
experiments. D-F. AZD1775-sensitive and -resistant Molm13 (D), Jurkat (E), and REH (F)
cells were treated with the indicated concentrations of vorinostat and/or 25-2000 nM
AZD1775 for 72 hr. Viable cell counts normalized to cells receiving no AZD1775 treatment
(NT) are shown. Results are shown as mean ± SEM from a minimum of three independent
experiments.
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Table 5.1. AZD1775 IC50 values of sensitive and resistant cells treated with HDAC 
inhibitors 
Molm13 
Condition AZD1775 IC50 (nM) 
Sensitive 249.5 
Resistant 1719 
Resistant 0.5 µM vorinostat 889.8 
Resistant 1 µM vorinostat 379.9 
Resistant 5 nM panobinostat 673.2 




Resistant 0.5 µM vorinostat 1306 
Resistant 1 µM vorinostat 453 
Resistant 5 nM panobinostat 1288 




Resistant 0.5 µM vorinostat 514.5 
Resistant 1 µM vorinostat 307.3 
Resistant 5 nM panobinostat 477.9 
Resistant 10 nM panobinostat 336.8 
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Figure 5.5. HDAC inhibition enhances DNA damage and apoptosis in resistant cells 
treated with AZD1775. A-C. AZD1775-sensitive and -resistant Molm13 (A), Jurkat (B), 
and REH (C) cells were treated with panobinostat (10 nM), vorinostat (1 µM), and/or 
AZD1775 (500 nM or 1000 nM) for 24 hr and stained with Annexin V-PE. Results are 
displayed as mean ± SEM of three independent experiments. *, P < 0.05. **, P < 0.01. ***, P 
< 0.001. ****, P < 0.0001. D-F. AZD1775-sensitive and -resistant Molm13 (D), Jurkat (E), 
and REH (F) cells were treated with panobinostat (10 nM), vorinostat (1 µM), and/or 
AZD1775 (500 nM or 1000 nM) for 24 hr after which protein lysates were subjected to 
western blotting with antibodies specific to PARP, γH2AX, and actin. 
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γH2AX, in resistant cells treated with AZD1775 (Figure 5.5d-f). 
HDAC inhibition results in cell cycle arrest due to increased expression of p21 
(Finzer et al., 2001). Therefore, I questioned whether altered cell cycle progression could 
contribute to the re-sensitization to AZD1775 that occurs with HDAC inhibition. Consistent 
with previous reports (Beck et al., 2010), inhibition of WEE1 lead to arrest in S phase in all 
three AZD1775-sensitive cell lines as well as an increase in cells in G2/M phase in Jurkat 
and REH AZD1775-sensitive cells (Figure 5.6a-c). This cell cycle arrest does not occur in 
AZD1775-resistant cells. Treatment of resistant cells with HDAC inhibitors produces a slight 
increase in S and/or G2/M phase cells (Figure 5.6a-c). However, this cell cycle arrest is less 
pronounced than that in sensitive cells treated with AZD1775. Thus, while altered cell cycle 
progression might contribute to the increased sensitivity to AZD1775, it does not appear to 
be the primary mechanism by which HDAC inhibitors restore sensitivity to AZD1775 in 
resistant cells.  
Zhou et al. reported treatment with HDAC inhibitors including vorinostat synergized 
with AZD1775 in AML cells without acquired resistance to WEE1 inhibition, and I was able 
to corroborate this in AZD1775-sensitive cell lines (Figure 5.7). Zhou et al. demonstrated 
that AZD1775 treatment lead to increased phosphorylation of CHK1 which promoted repair 
of DNA damage, and HDAC inhibition abrogated CHK1 phosphorylation leading to 
decreased DNA damage repair and subsequent apoptosis (Zhou et al., 2015). Thus, I sought 
to determine whether resistance to AZD1775 was the result of increased CHK1 activity 
promoting DNA damage repair. AZD1775 treatment promoted increased phosphorylation of 
CHK1 in Jurkat cells sensitive to AZD1775 (Figure 5.6d). AZD1775-resistant Jurkat cells do 
not have increased CHK1 phosphorylation with AZD1775, and this is not increased with  
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Figure 5.6. Cell cycle analysis and CHK1 phosphorylation in AZD1775-sensitive and 
resistant cells treated with HDAC inhibitors and/or AZD1775. A-C. AZD1775-sensitive 
and -resistant Molm13 (A), Jurkat (B), and REH (C), cells were treated with panobinostat (10 
nM), vorinostat (1 µM), and/or AZD1775 (1 µM) for 24 hr then fixed and stained with 
propidium iodide. Results are shown as mean ± SEM from three independent experiments. D. 
AZD1775-sensitive and -resistant Jurkat cells were treated with panobinostat (10 nM), 
vorinostat (1 uM), and/or AZD1775 (0.5 µM or 1 µM) for 24 hr after which protein lysates 
were subjected to western blotting with antibodies specific to pCHK1 serine 345 and actin. 
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Figure 5.7. HDAC inhibition enhances the anti-proliferative effects of AZD1775 in cells 
without acquired AZD1775 resistance. A-C. AZD1775-sensitive Molm13 (A), Jurkat (B), 
and REH (C) cells were treated with the indicated concentrations of panobinostat and/or 25-
2000 nM AZD1775 for 72 hr. Viable cell counts are normalized to cells receiving no 
AZD1775 treatment (NT). Results are shown as mean ± SEM from a minimum of 3 
independent experiments. D-F. AZD1775-sensitive Molm13 (D), Jurkat (E), and REH (F) 
were treated with the indicated concentrations of vorinostat and/or 25-2000 nM AZD1775 for 
72 hr. Viable cell counts are normalized to cells receiving no AZD1775 treatment (NT). 
Results are shown as mean ± SEM from a minimum of 3 independent experiments. 
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HDAC inhibition (Figure 5.6d). Thus, increased DNA damage repair mediated by 
ATR/CHK1 is not responsible for resistance to AZD1775. 
Inhibition of KDM5 Enhances the Anti-Proliferative Effects of AZD1775 in Resistant Cells 
Previous reports have demonstrated that inhibition of HDACs abrogates drug 
resistance by reducing the activity of KDM5A, an enzyme that removes di- and tri-methyl 
groups from histone 3 lysine 4 (Banelli et al., 2015; Sharma et al., 2010). Therefore, I 
questioned whether HDAC inhibition altered H3K4me3 in resistant cells treated with 
AZD1775. AZD1775 increases H3K4me3 in sensitive cells but not in resistant cells (Figure 
5.8a-c). The increase in H3K4me3 in sensitive cells is accompanied by decreased levels of 
KDM5A while KDM5A remains elevated in resistant cells treated with AZD1775. The 
increase in H3K4me3 and decrease in KDM5A in response to WEE1 inhibition are restored 
in resistant cells treated with panobinostat or vorinostat (Figure 5.8a-c). Notably, upon 
WEE1 inhibition, I observed increased levels of histone H3 in sensitive, and to a lesser 
extent, resistant cell lines, consistent with a role for WEE1 in regulating histone expression 
levels through the cell cycle (Mahajan et al., 2012), which contributes to the finding of 
increased signal for H3K4me3. Nonetheless, treatment with an inhibitor of KDM5 isoforms, 
CPI-455, enhanced the anti-proliferative effects of AZD1775 in resistant Molm13 and Jurkat 
cells (Figure 5.8d,e). CPI-455 treatment did not sensitize resistant REH cells to AZD1775 
(Figure 5.8f). Thus, in combination with AZD1775, HDAC inhibition reduces KDM5A 
protein levels and increases H3K4me3 in all resistant cell lines, and inhibition of KDM5 
enhances sensitivity to AZD1775 in two of three resistant lines. This suggests altered histone 
methylation contributes to AZD1775 resistance, at least in Molm13 and Jurkat cells, and also 
highlights differences in the mechanism of AZD1775 resistance in REH cells. 
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Figure 5.8. Altered H3K4 trimethylation contributes to AZD1775 resistance. A-C. AZD1775-sensitive and -resistant Molm13 
(A), Jurkat (B), and REH (C) cells were treated with panobinostat (10 nM), vorinostat (1 µM), and/or AZD1775 (0.5 µM or 1 µM) for 
24 hr after which protein lysates were subjected to western blotting with antibodies specific to H3K4me3, histone H3, KDM5A, and 
actin. D-F. AZD1775-sensitive and -resistant Molm13 (D), Jurkat (E), and REH (F) cells were treated with the indicated 
concentrations of CPI-455 and/or 50-2000 nM AZD1775 for 72 hr. Viable cell counts are normalized to cells receiving no AZD1775 
treatment (NT). Results are displayed as mean ± SEM from 3 independent experiments.
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c-MYC Expression is Regulated by HDACs and Contributes to AZD1775 Resistance
Next, I sought to identify changes in gene expression between AZD1775-sensitive 
and -resistant cells treated with AZD1775 and/or panobinostat. To accomplish this, 
AZD1775-sensitive and -resistant Jurkat cells were treated with panobinstat and/or AZD1775 
for 24 hours, and extracted RNA was subjected to RNAseq. Ingenuity Pathway Analysis 
identified increased expression of c-MYC and corresponding changes in expression of c-
MYC target genes in resistant cells treated with AZD1775 compared with sensitive cells 
treated with AZD1775 (Figure 5.9a). Addition of panobinostat to resistant cells treated with 
AZD1775 resulted in decreased c-MYC expression as well as altered expression of some c-
MYC target genes (Figure 5.9b). I next asked whether altered c-MYC transcription lead to 
comparable changes at the protein level. Indeed, elevated c-MYC protein levels were 
observed in all three resistant cell lines treated with AZD1775 compared with sensitive cells, 
and this was reduced by addition of panobinostat or vorinostat (Figure 5.10a-c). To 
determine whether increased c-MYC expression could be contributing to resistance to 
AZD1775, I treated each resistant cell line with JQ1. JQ1 is a small-molecule inhibitor of the 
bromodomain and extraterminal domain (BET) family proteins that has been shown to 
reduce c-MYC expression and inhibit MYC-dependent transcription by reducing activity of 
BET family member BRD4 (Venkataraman et al., 2014; Zuber et al., 2011). Consistent with 
a role for c-MYC in mediating resistance to AZD1775, treatment with JQ1 enhanced the 
anti-proliferative effects of AZD1775 in each resistant cell line (Figure 5.10d-f). Together, 
these results indicate that AZD1775-resistant cells have elevated c-MYC expression which 
can be abrogated by HDAC inhibition, and treatment with JQ1 can partially restore 
sensitivity to AZD1775.  
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Figure 5.9. AZD1775-resistant Jurkat cells have elevated c-MYC expression which is abrogated with panobinostat treatment. 
A. Ingenuity Pathways Analysis network map of gene fold change values of AZD1775-resistant Jurkat cells treated with AZD1775
(1000 nM) compared with AZD1775-sensitive Jurkat cells treated with AZD1775 (1000 nM). Genes in red have increased expression
in resistant cells while those in green have decreased expression in resistant cells compared with sensitive cells.  B. Ingenuity
Pathways Analysis network map of gene fold change values of AZD1775-resistant Jurkat cells treated with panobinostat (10 nM) and
AZD1775 (1000 nM) compared with resistant cells treated with AZD1775 (1000 nM) alone. Genes displayed in red have increased
expression while those displayed in green have decreased expression in resistant cells treated with panobinstat and AZD1775
compared with cells treated with AZD1775 alone.
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Figure 5.10. c-MYC expression contributes to AZD1775 resistance. A-C. AZD1775-sensitive and -resistant Molm13 (A), Jurkat 
(B), and REH (C) cells were treated with panobinostat (10 nM), vorinostat (1 µM), and/or AZD1775 (0.5 µM or 1 µM) for 24 hr after 
which protein lysates were subjected to western blotting with antibodies specific to c-MYC and actin. D-F. AZD1775-sensitive and -
resistant Molm13 (D), Jurkat (E), and REH (F) cells were treated with the indicated concentration of JQ1 and/or 50-2000 nM 
AZD1775 for 72 hr. Viable cell counts normalized to cells receiving no AZD1775 treatment (NT) are shown. Results are displayed as 
mean ± SEM from three independent experiments
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Summary of Findings 
Despite promising pre-clinical studies examining the effects of WEE1 inhibition 
alone or in combination with DNA damaging agents, clinical resistance to AZD1775 is likely 
to occur. To anticipate potential mechanisms of resistance, our group generated resistance to 
AZD1775 in three acute leukemia cell lines. Despite resistance to the anti-proliferative and 
DNA damage-inducing effects of AZD1775, drug treatment reduced WEE1 activity in 
resistant cells indicating resistance is not the result of elevated drug efflux or development of 
a gatekeeper mutation in the WEE1 gene. Resistance to AZD1775 was partially reversed after 
prolonged culture in drug-free media, consistent with a non-mutational mechanism of 
resistance. Furthermore, this reversibility suggests patients who develop resistance to 
AZD1775 may benefit from re-treatment after a “drug holiday.” AZD1775-resistant Molm13 
cells were less sensitive to vincristine but not to cytarabine while AZD1775-resistant Jurkat 
and REH cells were equally as sensitive to the anti-proliferative effects of vincristine and 
cytarabine as matched AZD1775-sensitive cells. This suggests some differences exist 
between the three resistant cell lines, and a better understanding of the mechanisms of 
resistance to AZD1775 will be useful in identifying these differences. While this data does 
not confirm resistance to AZD1775 is pathway specific, it does demonstrate that cells 
resistant to AZD1775 are not broadly drug resistant. This further confirms that increased 
drug efflux is not the primary mechanism of AZD1775 resistance and suggests resistant cells 
have not gained an enhanced ability to repair all types of DNA damage. Although AZD1775-
resistant cells maintain sensitivity to Ara-C, these cells are resistant to the combinatorial 
activity of AZD1775 and Ara-C. As a clinical trial examining AZD1775 combined with Ara-
C has recently been approved (NCT0266950), the findings in this study could be 
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immediately clinically relevant. Future studies examining whether these cells are resistant to 
AZD1775 combined with additional DNA damaging agents and whether HDAC inhibition 
can restore sensitivity to AZD1775 and Ara-C are warranted.  
This study demonstrates that pan-HDAC inhibition can enhance the anti-proliferative 
effects of AZD1775 in resistant cells, likely by increasing DNA damage and apoptosis. 
Consistent with previous reports demonstrating a role for altered H3K4me3 in drug 
resistance (Banelli et al., 2015; Sharma et al., 2010), AZD1775 promotes increased 
H3K4me3 and reduced protein levels of KDM5A in sensitive cells but not in resistant cells, 
and both events are restored in resistant cells treated with HDAC inhibitors. Furthermore, 
pharmacologic inhibition of KDM5 isoforms enhanced the anti-proliferative effects of 
AZD1775 in resistant Molm13 and Jurkat cells. Notably, CPI-455 inhibits all KDM5 
isoforms, so I cannot conclude that resistance to AZD1775 is primarily mediated by the 
KDM5A isoform. The confirmed role of KDM5A in mediating resistance to gefitinib in 
NSCLC cells (Sharma et al., 2010) and to temozolomide in glioblastoma cells (Banelli et al., 
2015) suggests KDM5A could be the primary KDM5 isoform responsible for AZD1775 
resistance in Molm13 and Jurkat; however, future studies are required to understand the 
contribution of KDM5 isoforms to resistance to AZD1775. 
I identified increased expression of c-MYC in resistant cells treated with AZD1775 
which was reduced with HDAC inhibition. This is consistent with previous reports 
demonstrating HDAC inhibition leads to decreased c-MYC expression (Li et al., 2009; 
Nebbioso et al., 2017). Consistent with a role for c-MYC in resistance to AZD1775, 
treatment with JQ1 partially sensitized resistant cells to AZD1775. As JQ1 is not a direct 
inhibitor of c-MYC, it will be necessary to confirm that reduced c-MYC levels can enhance 
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sensitivity to AZD1775 by shRNA-mediated knockdown of c-MYC or by inhibiting c-MYC 
function by abrogating the MYC/MAX interaction. While JQ1 treatment shifts the AZD1775 
dose response curve in resistant cells, the shift is less dramatic than in resistant cells treated 
with HDAC inhibitors suggesting c-MYC is likely one of several genes regulated by HDACs 
that contributes to WEE1 inhibitor resistance.   
In conclusion, this report describes the generation and characterization of three 
AZD1775-resistant acute leukemia cell lines. HDAC inhibition or reduction of c-MYC 
expression via JQ1 treatment sensitized each of the resistant cell lines to AZD1775 
suggesting increased c-MYC expression mediated by HDAC activity could be a mechanism 
employed by cell lines with diverse genetic backgrounds to achieve AZD1775 resistance. 
This work adds to a growing body of evidence indicating chromatin modifications mediated 
by HDACs and KDM5A can promote resistance to both targeted and non-targeted drugs. 
Further work is required is gain a complete understanding of the mechanism of AZD1775 
resistance; however, this work provides preliminary evidence for a mechanism of AZD1775 
resistance that could potentially be addressed by addition of HDAC inhibitors.  
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CHAPTER VI 
CONCLUSIONS AND FUTURE DIRECTIONS 
While survival rates for some patients with acute leukemia have improved in recent 
decades, the prognosis for patients who relapse or cannot tolerate standard chemotherapy is 
poor (Fernandez et al., 2009; Lowenberg and Rowe, 2016). As optimization of chemotherapy 
regimens has contributed to increased survival in AML and ALL patients, one promising 
strategy to further improve outcomes is addition of targeted agents to enhance the efficacy of 
drugs currently used to treat these diseases. Our lab and others have identified WEE1 as a 
promising target in cancer cells treated with DNA damaging agents (Harris et al., 2014; 
Porter et al., 2012; Tibes et al., 2012). As combinations with AZD1775 progress to clinical 
trials, a better understanding of the consequences of WEE1 inhibition in combination with 
targeted and non-targeted agents is necessary to ensure patients receive maximal therapeutic 
benefit from these combinations. This dissertation seeks to further the understanding of the 
effects of WEE1 inhibition in acute leukemia. In Chapter III, I determined that increased 
activity of WEE1 targets CDK1 and CDK2 is necessary for the combinatorial activity of a 
previously described synergistic combination, AZD1775 and cytarabine. In Chapter IV, I 
identified a novel synergistic combination, AZD1775 and olaparib, for the treatment of acute 
leukemia. Inhibition of WEE1 impaired HR in cells treated with olaparib, suggesting that 
WEE1 inhibition could allow for the clinical expansion of PARP inhibitors beyond their 
current use in BRCA1/2 mutant cancers. In Chapter V, I presented the first described 
mechanism of acquired resistance to AZD1775. In this final chapter, I discuss conclusions 
that can be drawn from these data, outline future directions to enhance clinical translation of 
drug combinations with AZD1775, and discuss potential roles for WEE1 in leukemogenesis.  
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The Requirement of CDK1 and CDK2 for the Combinatorial Activity of AZD1775 and 
Ara-C 
Previous studies have demonstrated synergy between AZD1775 and Ara-C (Ford et 
al., 2015; Porter et al., 2012; Tibes et al., 2012); however, a mechanistic understanding of 
this combination has remained elusive. Therefore, I sought to understand the requirement of 
WEE1 targets CDK1 and CDK2 for the combinatorial activity of AZD1775 and Ara-C. As 
described in Chapter III, expression of “WEE1 resistant” CDK1-AF and CDK2-AF, but 
neither alone, reduced cell viability and increased DNA damage and apoptosis in response to 
Ara-C in a T-ALL cell line. Further supporting my hypothesis that increased activity of 
CDK1 and/or CDK2 is required for the combinatorial activity of AZD1775 and Ara-C, 
pharmacologic inhibition of CDK1 alone or CDK1 and CDK2 together limited the reduction 
in viability that occurs in cells treated with Ara-C and AZD1775. Much of the literature 
reporting that WEE1 inhibition sensitizes malignant cells to DNA damaging agents focuses 
on the role of WEE1 in regulating CDK1 activity at the G2/M transition; however, my data 
indicate that increased activity of CDK2 is also required to sensitize cells to Ara-C. This 
suggests that the role of WEE1 in the DNA damage response extends beyond regulation of 
the G2/M transition and underscores the importance of WEE1 in coordinating progress 
though the cell cycle.  
Although these data lend insight into the contribution of CDK1 and CDK2 to the 
combinatorial activity of AZD1775 and Ara-C, much work remains to be done to gain a 
complete understand of the mechanisms by which AZD1775 sensitizes cells to Ara-C. First, 
validation of the genetic models used in this study is required. Although others have 
demonstrated that expression of CDK1/2-AF results in increased CDK activity, it will be 
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necessary to confirm this in Jurkat cells expressing these constructs. One limitation to these 
models is that they possess mutations resulting in amino acid substitutions at the site 
phosphorylated by WEE1, tyrosine 15, as well as the site phosphorylated by MYT1, 
threonine 14. Therefore, expression of these constructs more closely mimics inhibition of 
WEE1 and MYT1 and could produce a more substantial reduction in cell viability compared 
with cells with WEE1 knockdown or inhibition. Additionally, while results from assays using 
inhibitors of CDK1 and/or CDK2 in combination with AZD1775 and Ara-C are consistent 
with results from cells expressing CDK1/2-AF, these drugs do have off-target effects at 
higher concentrations (Cicenas et al., 2015; Vassilev et al., 2006). Therefore, determining 
whether shRNA-mediated knockdown of CDK1 or CDK2 can abrogate the combinatorial 
activity between AZD1775 and Ara-C could be performed to complement the experiments 
utilizing small-molecule CDK inhibitors. It should be noted, however, that CDK1 can 
compensate for the loss of CDK2 (Santamaria et al., 2007), so determining the relative 
contribution of CDK1 and CDK2 via shRNA-mediated knockdown might be challenging. 
Although these data indicate increased activity of CDK1 and CDK2 is necessary for 
sensitization to Ara-C in response to WEE1 inhibition, this work has not examined whether 
mechanisms independent of CDK1 and CDK2 contribute as well. If WEE inhibition 
sensitizes cells to Ara-C exclusively by increasing CDK1 and CDK2 activity, AZD1775 
would not be expected to further sensitize cells expressing CDK1-AF and CDK2-AF to Ara-
C. However, the discrepancy in γH2AX levels in cells treated with AZD1775 and Ara-C
compared to cells expressing both CDK constructs treated with Ara-C suggests that 
AZD1775 might also promote DNA damage induction through mechanisms independent of 
CDK1 and CDK2. In addition to inhibiting CDK1 and CDK2, WEE1 also regulates histone 
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gene transcription by phosphorylating histone H2B. Altered nucleosome to DNA ratios 
contribute to genome instability (Mahajan and Mahajan, 2013). Thus, it is possible that 
altered histone H2B phosphorylation could contribute to the increase in DNA damage that 
occurs in cells treated with AZD1775 and Ara-C. Alternatively, off-target effects of 
AZD1775 or changes in signaling in unidentified WEE1 substrates could contribute to DNA 
damage induction in cells treated with the combination. Interestingly, while cells expressing 
CDK1-AF and CDK2-AF appear to accumulate less DNA damage when treated with Ara-C 
compared with cells exposed to the WEE1 inhibitor, apoptosis induction as measured by 
cleaved PARP is roughly equivalent between these two conditions. This suggests that 
increased activity of CDK1 and CDK2 could enhance sensitivity to Ara-C by inducing 
apoptosis independently of DNA damage induction. Possible mechanisms for this are 
described below. 
Potential Roles of CDK1 and CDK2 in Sensitization to Ara-C 
CDK1 and CDK2 phosphorylate many substrates, so increased activity of these 
proteins could cooperate in a number of ways to sensitize cells to Ara-C. First, increased 
activity of CDK1 and CDK2 could prevent cell cycle arrest at the intra-S and/or G2/M 
checkpoints. The Porter lab previously determined that AZD1775 abrogates S-phase arrest in 
cytarabine-treated cells but does not promote a significant increase in unscheduled mitosis 
(Ford et al., 2015; Van Linden et al., 2013). However, others have demonstrated an increase 
in premature mitosis in AML cells treated with Ara-C and AZD1775 (Tibes et al., 2014). To 
understand these contrasting reports, it will be necessary to determine if expression of 
CDK1-AF and CDK2-AF promotes unscheduled mitosis Jurkat cells and other cell lines and 
whether abrogation of the G2/M checkpoint is necessary for the combinatorial activity of 
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AZD1775 and Ara-C. Cuneo et al. demonstrated that the G2/M checkpoint arrest in response 
to AZD1775 and radiation occurs in some, but not all, cell lines sensitive to this combination, 
and is a coincidental finding rather than a mechanism of synergy (Cuneo et al., 2016). 
Therefore, while AZD1775 might abrogate the G2/M checkpoint and/or promote premature 
mitosis in response to Ara-C treatment, it will be necessary to determine whether these 
events are coincidental observations or contributors to combinatorial activity.  
Second, increased CDK1 and CDK2 activity could sensitize cells to Ara-C by 
impairing HR, increasing replication fork firing and/or decreasing cellular nucleotide pools. 
Ara-C is incorporated into DNA during replication resulting in SSBs and stalled replication 
forks (Ewald et al., 2008), and stalled replication forks are frequently repaired by HR (Iraqui 
et al., 2012). Indeed, HR is the major survival mechanism in AML cells treated with 
sapacitabine, a nucleoside analogue derivative of Ara-C (Liu et al., 2010). As inhibition of 
WEE1 and forced activation of CDK1 results in impaired HR (Krajewska et al., 2013), 
AZD1775 could sensitize cells to Ara-C by preventing HR-mediated DNA damage repair. 
Additionally, hyperactivation of CDK1 and CDK2 in response to WEE1 inhibition results in 
firing of an increased number of origins of replication (Beck et al., 2012). This could result in 
increased incorporation of Ara-C into replicating DNA leading to an increase in DNA 
damage. Supporting the hypothesis that impaired HR and increased replication fork firing 
could contribute to the combinatorial activity of AZD1775 and Ara-C, Tibes et al. 
demonstrated that AML cells treated with AZD1775 and Ara-C displayed altered S-phase 
kinetics, de-regulated replication fork firing, and impaired homologous recombination (Tibes 
et al., 2014). Additionally, inhibition of WEE1 could enhance DNA damage accumulation in 
cells treated with Ara-C by promoting nucleotide pool imbalance. Inhibition of WEE1 
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reduces nucleotide pools by increasing nucleotide consumption and decreasing nucleotide 
production (Pfister et al., 2015). Ara-C competes with deoxycytidine triphosphate for 
incorporation into DNA (Ewald et al., 2008), so reduced cellular levels of nucleotides could 
lead to increased incorporation of Ara-C into DNA and enhanced DNA damage induction. 
Increased activity of both CDK1 and CDK2 is required for the reduction in nucleotide pools 
that occurs in AZD1775-treated cells (Pfister et al., 2015), which is consistent with my 
observations of a requirement for both CDK1 and CDK2 for the combinatorial activity of 
AZD1775 and Ara-C. 
Finally, increased CDK1 and CDK2 activity could function to increase pro-apoptotic 
signaling in cells treated with Ara-C. Both CDK1 and CDK2 have been shown to alter 
apoptotic signaling cascades. For example, CDK1 phosphorylates BAD to prevent its 
sequestration by 14-3-3 proteins (Konishi et al., 2002). CDK1 also potentiates the pro-
apoptotic functions of Bcl-2 in cells treated with microtubule interfering agents (Zhou et al., 
2014). Additionally, CDK1 promotes phosphorylation and degradation of the anti-apoptotic 
protein Mcl-1 which releases the pro-apoptotic protein BAK from sequestration (Chu et al., 
2012). CDK2-mediated phosphorylation of Bcl-xL switches the function of this protein from 
opposing to promoting apoptosis (Megyesi et al., 2016). The Porter lab has previously 
demonstrated that combined treatment with AZD1775 and Ara-C results in increased 
phosphorylation of histone H2AX at tyrosine 142, an event shown to promote apoptosis over 
DNA damage repair (Cook et al., 2009; Ford et al., 2015). Although the mechanism by which 
histone H2AX tyrosine 142 phosphorylation promotes apoptosis is unknown, this suggests 
that increased CDK1 and CDK2 activity could increase pro-apoptotic signaling in response 
to Ara-C treatment. Future studies are required to determine if any, or all, of these functions 
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of CDK1 and CDK2 contribute to the combinatorial activity of AZD1775 and Ara-C. 
However, these data highlight the unique ability of WEE1 to regulate two CDK proteins 
involved in DNA replication, mitosis, and cell cycle arrest at two of three DNA damage 
checkpoints and suggest the role of WEE1 in cells treated with Ara-C could extend beyond 
regulation of the G2/M checkpoint.  
Pre-clinical Efficacy of AZD1775 Combined with Olaparib 
While olaparib has proven to be an effective treatment in BRCA1/2-mutant 
malignancies, the expansion of this drug to cancers lacking defects in the HR pathway has 
been limited (Bryant et al., 2005; Fong et al., 2010; Kim et al., 2015; Ledermann et al., 
2012). In Chapter IV of this dissertation, I demonstrate that inhibition of WEE1 sensitizes 
HR-competent cell lines to olaparib by impairing HR and promoting DNA damage 
accumulation and apoptosis. The precise mechanisms of cell death due to PARP inhibition in 
the context of impaired HR remain unresolved, with at least 4 models proposed (De Lorenzo 
et al., 2013). These models share the common endpoint of unresolved and accumulated DNA 
damage and apoptosis, which my data support. While the impairment of HR may contribute 
to the observed sensitization, WEE1 has multiple effects on the cell cycle and DNA damage 
repair pathways through its regulation of CDK1 and CDK2 that could also contribute to the 
sensitization to olaparib. Indeed, WEE1 inhibition results in stalled replication forks that 
require processing to avoid collapse, and PARP is required for recruitment of DDR proteins 
to stalled forks for processing and repair, suggesting that failure to repair stalled replication 
forks could also contribute to the observed combinatorial activity of AZD1775 and olaparib 
(Bryant et al., 2009; Dominquez-Kelly et al., 2011). 
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As previously discussed, early work describing WEE1 inhibition as an effective 
chemosensitizing agent suggested combinations with WEE1 inhibitors were only effective in 
cells lacking functional P53 (Hirai et al., 2010; Mizuarai et al., 2009b; Rajeshkumar et al., 
2011; Wang et al., 2001). However, previous work from the Porter lab has demonstrated that 
inhibition of WEE1 sensitizes AML and lung cancer cells to antimetabolite 
chemotherapeutics independent of P53 functionality (Van Linden et al., 2013). Likewise, this 
work demonstrates that AZD1775 synergizes with olaparib in both TP53 wild-type (MV4;11, 
Molm13, REH) and mutant (Jurkat) cell lines. Furthermore, in an isogenic model, inhibition 
of endogenous P53 failed to enhance the combinatorial effect of AZD1775 and olaparib 
suggesting that sensitivity to AZD1775 and olaparib is independent of P53 functionality in 
this context. Although this combination appears to be effective regardless of TP53 status, it is 
still likely to display selectivity for cancer cells as a number of malignancies, including 
AML, have increased expression of WEE1 compared to noncancerous controls (E. et al., 
2009; GI et al., 2012; Porter et al., 2012; T. et al., 2003). As noted, AZD1775 did not 
significantly enhance the combinatorial effect of olaparib in all cell lines; thus, this 
combination is likely to be effective in some, but not all, acute leukemia cells.  
In addition to my in vitro data, I have demonstrated that combined AZD1775 and 
olaparib treatment enhanced the survival of mice injected with a murine AML cell line. 
Notably, this cell line possesses a MLL-ENL fusion which has been shown to mediate 
resistance to PARP inhibitors via HOXA9-mediated upregulation of DDR genes (Esposito et 
al., 2015; Pardee et al., 2011). Thus, this combination could provide a novel treatment option 
for MLL-rearranged leukemias, which are frequently resistant to standard chemotherapies 
and are associated with a poor prognosis.  
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I also demonstrate that AZD1775 enhances the effects of olaparib in AML patient 
samples, suggesting this combination could be effective in some patients. Importantly, 
combined treatment with AZD1775 and olaparib enhances short-term apoptosis as well as 
colony formation after prolonged drug exposure indicating that cells exposed to the 
combination could be less likely to repopulate and induce disease recurrence than cells 
exposed to AZD1775 or olaparib alone.  
Clinical Considerations of AZD1775 Combined with Ara-C or Olaparib 
 One clinical study examining the efficacy of AZD1775 and Ara-C for the treatment 
of AML has recently been approved (NCT02666950), and two studies assessing AZD1775 
combined with olaparib in solid tumors are currently ongoing (NCT02511795, 
NCT02576444). However, additional pre-clinical studies aimed at identifying markers 
predictive of sensitivity, establishing biomarkers indicating response to treatment, optimizing 
the sequence of treatment, and assessing potential toxicities will aid in the design of future 
clinical trials. A recent clinical trial of AZD1775 combined with conventional 
chemotherapeutics including the anti-metabolite gemcitabine found that 10% of patients had 
a partial response while 56% of patients had stable disease (Leijen, 2016). As in this clinical 
study, it is reasonable to expect that some, but not all, patients will benefit from AZD1775 
combined with Ara-C or olaparib. Identifying biomarkers predictive of sensitivity will be 
useful in the design of clinical trials to target treatment to patients most likely to respond 
while excluding patients likely to experience toxicity with minimal added benefit. While 
determining the relative contribution of CDK1 and CDK2 is helpful in understanding the 
mechanism of combinatorial activity of AZD1775 and Ara-C, CDK1/2 are not frequently 
mutated or differentially expressed in cancer and are not likely to be suitable biomarkers 
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(Vermeulen et al., 2003). Likewise, while TP53 mutation status is thought to be a predictor 
of sensitivity to some combinations with AZD1775 (Hirai et al., 2009), sensitivity to 
AZD1775 combined with Ara-C or olaparib is not dependent on TP53 mutation status, 
suggesting this will not be a reliable biomarker for these combinations (Tibes et al., 2014; 
Van Linden et al., 2013). Tibes et al. performed a RNAi rescue screen and found that 
knockdown of members of the MRN complex which regulates HR reduced sensitivity to 
Ara-C and AZD1775 (Tibes et al., 2014). Thus, it is possible that this combination will be 
most effective in HR-competent cells. Supporting this, others have shown that cells with 
mutations in DNA damage repair proteins FANCC, FANCG, or BRCA2 are less sensitive to 
AZD1775 in combination with oxaliplatin indicating that an intact DDR pathway might be 
indicative of sensitivity to AZD1775 combined with some DNA damaging agents (Kausar et 
al., 2015; Lal et al., 2016). While ability to repair DNA damage via HR may be a useful 
biomarker for the treatment of Ara-C and AZD1775, this is not likely to be predictive of 
response to AZD1775 and olaparib as cells that were sensitive or resistant to the combination 
had increased Rad51 foci formation in response to olaparib treatment. RNAi screens or 
insertional mutagenesis in cells treated with AZD1775 and olaparib could be useful in 
identifying genes that mediate sensitivity to this combination.  
Similarly, identifying biomarkers indicative of response to treatment will be useful in 
aiding clinical decision-making concerning treatment strategies. Decreased phosphorylation 
of CDK1 at tyrosine 15 and gene expression signatures have been used to confirm target 
engagement in in vitro and in vivo assays (Ford et al., 2015; Harris et al., 2014; Mizuarai et 
al., 2009a); however, these markers are not indicative of tumor response to drug 
combinations. Our group has demonstrated an increase in phosphorylation of histone H2AX 
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at tyrosine 142 in cells treated with AZD1775 and Ara-C or vincristine but not with non-
synergistic combinations (Ford et al., 2015). Future studies are required to determine whether 
this phosphorylation event occurs in cells treated with olaparib and AZD1775 and if this 
phosphorylation event or other molecular markers could be used to anticipate clinical 
response in patients treated with AZD1775 and Ara-C or olaparib. 
For combinations with AZD1775 to achieve maximal clinical effect, it will be 
necessary to optimize treatment timing and sequence. The Porter and Vibhakar labs as well 
as others have demonstrated synergy between AZD1775 and DNA damaging agents when 
cells were exposed to both drugs simultaneously for three days or less (Harris et al., 2014; 
Porter et al., 2012; Tibes et al., 2012; Van Linden et al., 2013). Others have reported 
combinatorial activity between AZD1775 and 5-fluorouracil or gemcitabine when cells were 
pre-treated with DNA damaging agents followed by exposure to AZD1775 (Hirai et al., 
2009; Webster et al., 2017). However, it is unknown whether treatment with AZD1775 and 
DNA damaging agents simultaneously or sequentially yields greater synergy. One group 
demonstrating that combinatorial activity between AZD1775 and 5-fluorouracil was the 
result of increased DNA DSBs rather than premature mitosis postulates that longer term 
treatments with DNA damaging agents and AZD1775 may be more effective than short-term 
sequential treatments (Webster et al., 2017). Future studies examining optimal treatment 
timing and sequence in in vitro and in vivo models will be helpful in the design of clinical 
trials and has potential to assist in understanding the mechanism of combinatorial activity of 
AZD1775 and various DNA damaging agents.  
As drug combinations with AZD1775 are translated to the clinic, potential adverse 
effects must be considered. Combined treatment with AZD1775 and Ara-C resulted in 
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increased hematopoietic toxicity in mice treated with high Ara-C concentrations indicating 
that AZD1775 combined with high-dose Ara-C might be poorly tolerated in patients 
(unpublished data). Future studies are required to determine whether concentrations of Ara-C 
can be reduced when given in combination with AZD1775 in order to maintain efficacy 
while reducing side effects. This strategy could be used to increase treatment options in 
elderly patients who often tolerate high-dose Ara-C poorly. Additionally, a carboxylate 
methyl-ester derivative of AZD1775, designated CJM061, maintains synergy with cisplatin 
but has reduced single-agent toxicity (Matheson et al., 2016b). Therefore, additional studies 
are warranted to determine whether Ara-C combined with CJM061 is tolerated better than 
Ara-C combined with AZD1775.  It should be noted that two of the ten mice treated with 
AZD1775 and olaparib died with no evidence of leukemia. While mouse weights and 
complete blood counts suggest minimal drug toxicity after 7 days of treatment, future studies 
are necessary to assess cumulative toxicity with prolonged treatment. Although optimizations 
to dosing and the timing of treatments may be necessary, this combination is not expected to 
be particularly toxic, as both olaparib and AZD1775 have been used in multiple clinical trials 
with reasonable toxicity profiles (Do et al., 2015; Kim et al., 2015). Indeed, early results 
from a phase 1b clinical trial combining olaparib with AZD1775 for the treatment of 
refractory solid tumors suggest no dose-limiting toxicities (Hamilton et al., 2016). While 
combinations with AZD1775 may be tolerated short term, potential long-term effects should 
be considered. Inhibition of WEE1 results in replication stress which could contribute to 
genomic stability. Thus, as with all DNA damaging agents, potential for secondary 
malignancies must be considered. As inhibition of WEE1 induces DNA damage 
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accumulation in S-phase, the risk of secondary malignancies might be comparable to that of 
anti-metabolite chemotherapeutics. 
The Role of HDACs, KDM5, and c-MYC in AZD1775 Resistance 
 As described in Chapter V, I identified HDACs as a key mediator of resistance to 
AZD1775 in three acute leukemia cell lines. This study provides valuable insight into 
potential mechanisms of resistance to WEE1 inhibition. However, additional work is 
necessary to determine how HDACs accomplish resistance to AZD1775. Although HDAC 
activity appears to be required for AZD1775 resistance, the mechanism of altered HDAC 
activity between sensitive and resistant cells remains to be determined. RNAseq of sensitive 
and resistant cells treated with AZD1775 did not identify changes in HDAC expression. 
Thus, it is reasonable to hypothesize that post-translational modifications of HDACs increase 
HDAC activity or impair degradation in AZD1775-resistant cells. HDACs function as 
subunits in protein complexes, so HDAC activity could also be altered by changes in 
expression or activity of other proteins in these complexes. Future studies are required to test 
these hypotheses. 
Consistent with previous reports demonstrating that HDAC inhibition alters KDM5A 
expression and H3K4me3 in drug-resistant cells (Banelli et al., 2015; Sharma et al., 2010), I 
found resistant cells treated with AZD1775 have reduced H3K4me3 and increased KDM5A 
compared to sensitive cells treated with the WEE1 inhibitor, and both events are reversed 
with HDAC inhibition. Inhibition of KDM5 isoforms enhanced sensitivity to AZD1775 in 
resistant Jurkat and Molm13 but not REH cells. This could indicate that HDACs mediate 
resistance in REH cells through mechanisms different from those in Molm13 and Jurkat 
cells; however, it is also possible that KDM1A, another demethylase that regulates 
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H3K4me3, is capable of compensating for the loss of KDM5 in REH cells (Pajtler et al., 
2013). Additionally, it is unclear how KDM5A interacts with HDACs to produce resistance 
to AZD1775. KDM5A associates with two distinct HDAC complexes: the SIN3B-containing 
HDAC complex and the nucleosome remodeling and histone deacetylation (NuRD) complex 
(Nishibuchi et al., 2014). Both complexes contain HDAC1 and HDAC2 and are primarily 
associated with transcriptional repression. The NuRD complex regulates hematopoietic 
differentiation and represses gene transcription in cells that have accumulated DNA damage 
(Lai and Wade, 2011). SIN3B-containing HDAC complexes are involved in G0/G1 cell cycle 
control (Hayakawa and Nakayama, 2011). Future studies are required to understand the 
relative contribution of each complex to resistance to AZD1775. Furthermore, while I have 
demonstrated increased H3K4me3 in response to AZD1775 treatment in both sensitive cells 
and resistant cells treated with HDAC inhibitors, it is unclear whether this is the result of a 
global increase in H3K4me3 or an increase in promoter regions of specific genes. Thus, a 
better understanding of the location of altered histones and the effects on gene expression 
will be useful in understanding of the contribution of reduced H3K4me3 to AZD1775 
resistance. 
 RNAseq analysis identified increased expression of c-MYC in resistant cells treated 
with AZD1775 which was reduced with HDAC inhibition. c-MYC binds to and regulates the 
transcription of up to 15% of all genes and influences many cellular processes including cell 
cycle progression, DNA replication, survival, and differentiation (Patel et al., 2004). Thus, 
altered expression of many genes may contribute to AZD1775 resistance. Notably, c-MYC 
regulates multiple genes involved in nucleotide synthesis (Liu et al., 2008). Inhibition of 
WEE1 leads to nucleotide shortage and subsequent replication fork collapse (Beck et al., 
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2012), so c-MYC could function to increase nucleotide production in resistant cells. 
Increased nucleotide pools could prevent DNA damage accumulation in the context of WEE1 
inhibition, and this is consistent with the observations of reduced γH2AX and CHK1 
phosphorylation in resistant cells treated with AZD1775.  
Although increased c-MYC expression appears to contribute to AZD1775 resistance, 
it is unclear whether c-MYC levels are influenced by KDM5A activity. It is possible that 
KDM5A and c-MYC function in parallel pathways downstream of HDACs. Additionally, it 
not known whether inhibition of KDM5A influences HDAC activity. Since KDM5A 
associates with HDAC complexes (Nishibuchi et al., 2014), it is possible that inhibition of 
KDM5 proteins reduces c-MYC levels by impairing HDAC activity. Furthermore, KDM5A 
and KDM5B bind to c-MYC and function as co-activators to enhance c-MYC transcriptional 
activity (Secombe et al., 2007), so increased KDM5A in resistant cells treated with AZD1775 
could function to enhance c-MYC transcriptional activity rather than increase c-MYC 
expression. Reports of drug resistance driven by c-MYC or HDACs and KDM5A have 
demonstrated surviving cells have an increase in markers associated with cancer stem cells 
(Banelli et al., 2015; Sharma et al., 2010; Zhang et al., 2015), thus it will also be useful to 
determine whether altered activity of c-MYC, HDACs, and/or KDM5A promotes a cancer 
stem cell phenotype in AZD1775 resistant cells. Figure 6.1 summarizes how HDACs, 
KDM5A, and c-MYC produce AZD1775 resistance and highlight future work required to 
completely understand how these proteins interact in AZD1775 resistant cells. 
Understanding the Clinical Relevance of HDAC-Mediated AZD1775 Resistance 
In addition to gaining a complete understanding of the molecular mechanism of 




Figure 6.1. Proposed model for AZD1775 resistance. AZD1775-resistant cells have 
increased c-MYC expression and decreased H3K4me3 compared with sensitive cells. Pan-
HDAC inhibition restores sensitivity to AZD1775, reduces c-MYC expression, and restores 
H3K4me3 suggesting HDAC activity is likely increased in resistant cells and is the primary 
mediator of AZD1775 resistance. BET bromodomain inhibition via JQ1 which has 
previously been demonstrated to reduce c-MYC expression can partially abrogate AZD1775 
resistance. Likewise, treatment with CPI-455 which inhibits KDM5 isoforms, the family of 
histone demethylases that remove tri-methyl groups at H3K4, can partially abrogate 
AZD1775 resistance. Future studies are required to determine whether KDM5 proteins and 













clinical relevance of these findings. One caveat to these data is that it is unclear whether 
combined HDAC and WEE1 inhibition selectively kills cancer cells or whether HDAC 
inhibitors also sensitize non-cancerous cells to AZD1775. It will be necessary to assess the 
selectivity of this combination in order to determine whether combined treatment with 
HDAC inhibitors and AZD1775 could be tolerated in patients. Immortalized ALL cell lines 
display continuous proliferation while drug resistant cells in patients are typically more 
dormant. Patient-derived xenografts are useful in studying relapsed disease as these models 
have similar features to MRD in patients (Ebinger et al., 2016). Thus, generation of 
AZD1775 resistance in patient-derived AML and ALL xenografts could be more predictive 
of resistance mechanisms likely to occur in patients. A previous study confirming that HDAC 
inhibition abrogated resistance to gefitinib in NSCLC cells also demonstrated that combined 
treatment with HDAC inhibitors and gefitinib prevented the emergence of resistant clones 
(Sharma et al., 2010). Thus, it will be useful to determine whether treatment with 
panobinostat or vorinostat can prevent AZD1775 resistance in cell lines and patient samples 
with no previous exposure to AZD1775. This data would aid in the design of clinical trials as 
it could help discern whether upfront treatment with AZD1775 combined with an HDAC 
inhibitor or treatment with an HDAC inhibitor in relapsed patients previously treated with 
AZD1775 would be more beneficial. Furthermore, clinical use of pan-HDAC inhibitors is 
associated with toxicity (Hideshima et al., 2015), so a better understanding of which HDACs 
mediate AZD1775 resistance could allow for the use of more targeted and less toxic HDAC 
inhibitors. Additionally, determining whether c-MYC expression levels correlate with 
AZD1775 sensitivity in patient samples will be useful in understanding the clinical relevance 
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of the findings of this study and could provide support for the use of c-MYC expression as a 
biomarker for sensitivity to AZD1775. 
 Finally, while some studies have identified AZD1775 as an effective single-agent 
therapy, the majority of ongoing clinical trials are examining AZD1775 in combination with 
DNA damaging agents (Matheson et al., 2016a). In Chapter V, I demonstrate that cells 
resistant to AZD1775 monotherapy are also resistant to the combinatorial effects of 
AZD1775 combined with Ara-C. Future studies are necessary to determine whether HDAC 
inhibition can restore sensitivity to combined treatment with AZD1775 and Ara-C. 
Additionally, it will be necessary to determine whether AZD1775-resistant cells are less 
sensitive to AZD1775 combined with additional DNA damaging agents to gain a complete 
understanding of the clinical relevance of these findings. 
Potential Roles for WEE1 in Leukemogenesis 
 While many groups have studied inhibition of WEE1 as a chemosensitizing agent, a 
potential role for WEE1 in tumorigenesis has not been studied. Understanding if and how 
WEE1 contributes to leukemogenesis will be necessary to optimally design clinical trials 
with small-molecule WEE1 inhibitors. Constitutive activation of oncogenes induces 
replication stress through mechanisms including increased replication or origin firing (Zeman 
and Cimprich, 2014). Cancer cells are dependent on the function of non-mutated genes to 
reduce cellular stress, including replication stress, and promote survival. This phenomenon is 
known as non-oncogene addiction (Nagel et al., 2016). As WEE1 functions to prevent 
aberrant replication fork firing and maintain adequate cellular nucleotide pools, it is possible 
that WEE1 is a non-oncogene addiction in some contexts. Consistent with a role in buffering 
oncogenic stress, WEE1 is overexpressed in many cancers including AML (GI et al., 2012; 
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Harris et al., 2014; Porter et al., 2012). The Vibhakar lab has demonstrated that patients with 
MYC-driven medulloblastomas with high WEE1 expression have worse outcomes compared 
with medulloblastomas with lower levels of WEE1. Furthermore, MYC-driven 
medulloblastomas are more sensitive to WEE1 inhibition than medulloblastoma cells reliant 
on alternative oncogenes (unpublished data). This suggests that WEE1 could function to 
abrogate replication stress and promote tumorigenesis in medulloblastomas driven by the 
MYC-oncogene. As in medulloblastoma, it is possible that WEE1 functions as a non-
oncogene addiction in leukemia cells with specific oncogenic drivers. The Porter lab has 
demonstrated that expression of FLT3-ITD or MLL-AF9 oncogenes together or alone does 
not increase sensitivity to WEE1 inhibition (unpublished data). However, it will be useful to 
determine whether leukemia cells expressing other common oncogenes including K/N-RAS, 
c-KIT, and MYC are reliant on WEE1 for survival. As previously discussed, increased 
expression of c-MYC is associated with AZD1775 resistance in three acute leukemia cell 
lines. Therefore, it is possible that WEE1 dependence in cancer cells with common 
oncogenes is lineage-specific. 
 As potential roles for WEE1 in leukemogenesis are considered, it should be noted that 
an unbiased, systematic search for additional WEE1 substrates has not be performed. The 
Porter lab is taking steps to address this deficiency by performing a phospho-proteomic 
screen of cells with and without AZD1775 treatment using the stable isotope labeling with 
amino acids in cell culture (SILAC) method. Although follow-up experiments will be 
required to determine whether hits from the screen are the results of WEE1 inhibition or off-
target effects of the drug, understanding whether WEE1 can phosphorylate additional targets 




Inhibition of WEE1 via the small-molecule inhibitor AZD1775 is emerging as a 
promising strategy in leukemia and in other malignancies. As a chemosensitizing agent, 
AZD1775 has potential to enhance the efficacy of established drugs currently used to treat 
acute leukemia. Furthermore, AZD1775 might allow for dose reduction of some 
conventional chemotherapy agents which could provide therapeutic options for older patients 
who typically cannot tolerate the harsh side effects of chemotherapy. WEE1 might also 
function as a non-oncogene addiction in some contexts by compensating for oncogene-
induced replication stress. This dissertation contributes to the field of WEE1 biology by 
demonstrating that increased activity of both CDK1 and CDK2 is necessary for the 
combinatorial activity of AZD1775 and cytarabine. This highlights the unique role of WEE1 
in regulating two CDK proteins necessary for cell cycle progression, DNA replication, and 
mitosis. I have also demonstrated that inhibition of WEE1 is a promising strategy to impair 
homologous recombination and sensitize HR-competent cells to olaparib. This combination 
has potential to expand the use of olaparib outside its current use in BRCA1/2-mutant tumors. 
Finally, I demonstrate that AZD1775 resistance is regulated by HDAC-mediated 
overexpression of c-MYC in three genetically diverse acute leukemia cell lines. In addition to 
describing a mechanism of resistance to AZD1775, this work provides support for a growing 
body of evidence suggesting cancer cells can become resistant to targeted and non-targeted 
agents by adopting an altered chromatin state which is reversed with HDAC inhibition. In 
total, this work demonstrates that inhibition of WEE1 is a promising strategy for improving 
outcomes in acute leukemia and provides support for clinical trials examining the effects of 
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